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Abstract 
Type 1 diabetes was thought to be a disease of absolute insulin deficiency. 
However, recent evidence has shown that most people with Type 1 diabetes 
have persistent endogenous insulin production, even those with long disease 
duration. Close to diagnosis preserved beta cell function is associated with 
reduced HbA1c, hypoglycaemia and complication rates. However, very little is 
known about the clinical impact of persistent endogenous insulin in long 
duration diabetes. This thesis aims to assess the clinical impact of preserved 
beta cell function in long duration type 1 diabetes.  
During this analysis we identified the potential for glucagon to be used as a 
biomarker of hypoglycaemic risk. Intensive treatment is an integral part of 
diabetes management and is key to reducing the risk of both development and 
progression of microvascular complications. However, treatment induced 
hypoglycaemia poses a significant barrier to intensive treatment. Currently, 
prediction of those most at risk of hypoglycaemia is based on clinical 
information, such as diabetes duration, with no biomarkers used to assess 
hypoglycaemic risk. As such, this finding prompted an additional aim: to 
investigate the relationship between meal stimulated glucagon and 
hypoglycaemia in long duration type 1 diabetes. 
In Chapter 1 I review current evidence on the role and importance of persistent 
beta cell function in type 1 diabetes. 
In Chapter 2 I outline the methods of the TIGI Study, which provided the data 
for this project.  
In Chapter 3 I demonstrate that preserved beta cell function is associated with 
significantly reduced reported hypoglycaemia in long duration type 1 diabetes.  
In Chapter 4 I show that higher meal stimulated glucagon is associated with 
reduced hypoglycaemia rate in long duration type 1 diabetes, independent of 
HbA1c, C-peptide and disease duration.  
Chapter 5 discusses the findings of Chapters 3 and 4 and highlights areas for 
future research.   
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Structure and aims of thesis 
 
The aim of this thesis is to investigate the clinical implications of persistent beta 
cell function in long-duration type 1 diabetes. Whilst completing this analysis we 
identified the potential for glucagon to be used as a biomarker of hypoglycaemic 
risk. This led to the development of an additional aim: to investigate the 
relationship between stimulated glucagon and hypoglycaemia in long duration 
type 1 diabetes. 
Chapter 2 
Chapter 2 provides details on aspects of methodology relevant to both Chapters 
3 and 4, such as the design of the TIGI Study. More specific methods for each 
chapter, including statistical analysis, are outlined in the relevant chapters.  
Chapter 3 
Very little is known about the clinical impact of preserved beta cell function in 
long duration diabetes. This chapter aims to investigate the clinical impact of 
preserved beta cell function on hypoglycaemia, HbA1c and complications in a 
long duration type 1 diabetes cohort. 
Chapter 4 
During analysis for Chapter 3 we found there to be an association between 
mixed-meal tolerance test stimulated glucagon and hypoglycaemia rate. 
Ordinarily glucagon is secreted in response to hypoglycaemia and supressed 
following a meal. However, glucagon is known to be dysregulated in type 1 
diabetes. This chapter investigates the association between mixed-meal 
tolerance test stimulated glucagon and hypoglycaemia in long duration type 1 
diabetes.   
Chapter 5 
In this chapter I will summarise the findings of Chapters 3 and 4 and discuss 
their limitations, implications and potential directions for future research.   
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2.1 Type 1 Diabetes 
2.1.1 Autoimmune destruction 
Type 1 Diabetes is an autoimmune condition resulting in the progressive 
destruction of pancreatic beta cells, leading to insulin deficiency. Disease 
progression follows a sequence first proposed by Eisenbarth in 1986 which has 
since been modified, see Fig. 1. (1,8) The pathway begins with a genetically 
determined background risk, followed by triggering of autoimmune activation 
and development of measurable autoimmunity; currently the triggers for this are 
unknown but possibilities include environmental exposures and early life 
infections. (9) Individuals develop autoantibodies directed at the insulin-
producing beta cells of the pancreas, these antibodies can be present for a 
number of years prior to clinical onset. (10) Ordinarily beta cells regulate blood 
glucose levels to maintain homeostasis, secreting insulin in response to 
hyperglycaemia. In pre-clinical type 1 diabetes, beta cell mass gradually 
depletes without impacting glucose homeostasis, and individuals suffer no 
symptoms of diabetes. Eventually a critical beta cell mass is reached, at which 
point homeostasis can no longer be maintained. Dysregulation leads to 
increasingly elevated blood glucose levels and eventually symptoms such as 
polydipsia, polyphagia and polyuria become apparent and insulin treatment is 
required. Post-diagnosis it is common to experience a honeymoon period where 
remaining beta cell mass protects from insulin induced hypoglycaemia and 
good blood glucose control is easily achieved. (1)  
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Fig. 1: “The natural history of type 1 diabetes”, modified from Eisenbarth’s 
original 1986 model. Taken from Atkinson et al.  (1) 
 
 
Traditionally it was thought that this depletion progressed to complete beta cell 
loss resulting in total insulin deficiency. Recent evidence suggests a two stage 
decline in beta cell function. Initially there is a substantial decline in function for 
approximately 7 years, this is followed by a plateau in which there is minimal 
further loss of beta cell function, see Fig. 2. This suggests that at approximately 
7 years there is a change in the disease process. Perhaps the immune process 
changes or there are a remaining cohort of beta cells that have evaded 
autoimmune destruction. (2) 
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Fig.2: Decline of beta cell function in type 1 diabetes, as measured by Urinary 
C-peptide-Creatinine ratio (UCPCR) –described later in text. Taken from 
Shields et al. (2) 
 
 
2.1.2 Genetic influence  
Genetic susceptibility is a key component of the development of type 1 
diabetes, with an identical twin concordance of up to 70% and 10% of cases 
having an affected first degree relative. (11) Type 1 diabetes is a polygenic 
disease with over 50 predominantly immune loci identified so far. (12) The 
major genetic loci driving genetic risk are the antigen presentation genes of the 
immune system in the HLA region. In type 1 diabetes the HLA class 2 DR-DQ 
haplotypes DR3-DQ2 and DR4-DQ8 are the strongest risk haplotypes. 
Environmental influences impact this genetic background risk and could have 
an effect as early as in utero. A popular explanation is the hygiene hypothesis, 
in which a lack of childhood infections is thought to increase susceptibility to 
autoimmune conditions. (9,11,13,14)  
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2.1.3 Epidemiology 
Type 1 diabetes is one of the most common chronic diseases of childhood. 
Worldwide incidence is increasing by 2-5% and in the UK prevalence in those 
under 15 years is predicted to increase from 19,000 in 2005 to 33,000 in 2020. 
(15,16) In the past type 1 diabetes had been viewed as a childhood disease, 
commonly referred to as juvenile onset diabetes. However, whilst diagnosis is 
classically made in childhood the incidence may be much higher in adults than 
previously thought. (17) Unlike most autoimmune conditions type 1 diabetes 
affects slightly more males than females. Type 1 diabetes diagnostic criteria 
are: a fasting blood glucose >7.7mmol/l or any blood glucose >11.1mmol/l 
accompanied with symptoms of hyperglycaemia. (1) Due to severe insulin 
deficiency once the diagnosis of type 1 diabetes is made patients are started on 
injected insulin treatment.  
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2.2 Complications of diabetes  
 
This section reviews complications of diabetes with particular focus on 
hypoglycaemia, retinopathy and nephropathy as they are the major focus of the 
research chapters in this thesis. 
The discovery of insulin in 1921-22 transformed a type 1 diabetes diagnosis 
from being a death sentence to a chronic condition. (1) However, living with 
diabetes leaves individuals at risk of acute and chronic complications, with high 
mortality and morbidity. A recent Scottish type 1 diabetes cohort study 
compared individuals with and without type 1 diabetes at 20 years old, 
estimating an 11-13 year loss of subsequent life expectancy for those with type 
1 diabetes. (18) Management of complications is extremely costly and is the 
mainstay of NHS spending on diabetes. Currently diabetes is thought to use up 
to 10% of the NHS budget, costing approximately £1million per hour. (19) 
Prevention and effective management of complications is very important for 
people with diabetes and for funding of the NHS.  
Whilst persistent hyperglycaemia results in both macrovascular and 
microvascular complications, treatment induced hypoglycaemia can be equally 
damaging. It is recommended that individuals with type 1 diabetes self-monitor 
their blood glucose levels at least 4 times a day, before all meals and before 
sleep, so that they can adjust insulin dose accordingly. On waking a fasted level 
of 5-7mmol/l is recommended and before meals and during the day the aim is 
4-7mmol/l. Alternatively, for individuals who like to self-monitor after meals they 
must do so at least 90 minutes post-meal with a target of 5-9mmol/l. Clinicians 
also monitor blood glucose control using HbA1c. Circulating glucose binds to 
haemoglobin throughout the life of a red blood cell (approximately 120 days) 
and forms glycated haemoglobin (A1c), as such HbA1c provides an estimate of 
blood glucose over the last 3 months. This should be routinely measured every 
3-6 months with a target of <48mmol/l (6.5%) and insulin regimes adjusted 
accordingly. (20) Management consists of a balance between using insulin to 
avoid chronic complications and preventing life-threatening insulin induced 
hypoglycaemia.  
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2.2.1 Acute complications 
Acute complications include diabetic ketoacidosis (DKA) and hypoglycaemia.  
Diabetic ketoacidosis 
DKA typically occurs in unmanaged type 1 diabetes and is a way in which type 
1 diabetes may first present. Almost 4% of people with type 1 diabetes 
experience DKA each year. Common precipitants include intercurrent illness or 
lack of insulin administration. (21) Severe lack of insulin causes intracellular 
glucose deficit and results in the breakdown of fatty acids producing acidic 
ketone bodies. Metabolic acidosis occurs requiring immediate hospitalisation 
and fluid resuscitation. Diagnosis is made through confirmation of 
hyperglycaemia, ketosis and acidosis. (22) DKA is a medical emergency with a 
mortality rate of 3-5% and is responsible for a 54-76% of type 1 diabetes deaths 
in people with type 1 diabetes <30 years old. (21,23) 
Hypoglycaemia 
Hypoglycaemia is a serious and common problem in type 1 diabetes that occurs 
as a result of administration of exogenous insulin. It is biochemically defined as 
a blood glucose ≤3.9mmol/l and carries significant morbidity and mortality. 
Typically, individuals experience both autonomic and neuroglycopenic 
symptoms during hypoglycaemia. Common symptoms include sweating, 
weakness, drowsiness, loss of balance, visual disturbance and cognitive 
impairment. (24,25) These symptoms can have a substantial impact on quality 
of life; including increasing the risk of accidents and falls and causing driving 
licence restrictions. More serious symptoms include arrhythmias, myocardial 
ischaemia, seizure or coma. Beyond its immediate effects, hypoglycaemia can 
have long-term cardiac and neurological implications. (25) It has been reported 
that hypoglycaemia causes the death of 4-10% of patients with type 1 diabetes. 
(26)  
Commonly hypoglycaemia is categorised as mild or severe depending on 
whether the individual can self-treat. Mild hypoglycaemia is common, with 
adults experiencing an average of 1-2 episodes per week. However, 
quantification can be difficult due to reliance on patient recognition and recall. 
Prevalence of severe hypoglycaemia is approximately 30% per year. (25) Self-
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reported severe hypoglycaemia is associated with a 3.4 times increased risk of 
death at 5 years compared to those with mild or no hypoglycaemia. (27) 
Hypoglycaemic symptoms reduce with increased time spent at low blood 
glucose levels, resulting in reduced hypoglycaemic awareness. Hypoglycaemic 
awareness is a vital protector from severe hypoglycaemia. For this reason, 
hypoglycaemia typically occurs in those with long duration diabetes, with 
disease duration being an important predictor of hypoglycaemic risk. Additional 
risk factors for severe hypoglycaemia include strict glucose control, extremes of 
age, and sleep (approximately 50% of episodes occur during sleep). (25) 
Hypoglycaemia is the most serious limiting factor in achieving good glycaemic 
control in type 1 diabetes. (28,29) As such, patient education is key to 
maintaining tight control whilst preventing hypoglycaemia. It is important that 
patients frequently monitor their blood glucose levels and subsequently 
appropriately adjust their diet and insulin dose. New technologies including 
continuous glucose monitoring and modified insulin pumps are been developed 
and refined to help combat hypoglycaemia. (25) We still have an incomplete 
understanding as to why some individuals have more severe episodes of 
hypoglycaemia than others, this is likely due to both physiological and 
psychosocial factors.  
2.2.2 Chronic complications 
Chronic complications result from persistent hyperglycaemia damaging 
vasculature, with damage dependent on hyperglycaemic duration and severity. 
They are classified as microvascular and macrovascular. Microvascular 
complications include diabetic retinopathy, nephropathy and neuropathy.  
Microvascular 
Retinopathy 
Diabetic retinopathy is the most common microvascular complication of 
diabetes. (30) Amongst people with type 1 diabetes in the UK, prevalence is 
estimated to be approximately 55% (predominantly background retinopathy) 
with the vast majority developing retinopathy within 20 years of diagnosis. 
(31,32) Duration is a key risk factor for the development of retinopathy; each 5 
year increase in disease duration increases risk of diabetic retinopathy by 10% 
and severe diabetic retinopathy by 26%. (31)  
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Hyperglycaemia and hypertension damage retinal blood vessels. This can result 
in reduced blood supply damaging the retinal tissues. Vessels also develop 
microaneurysms and leak; causing macular oedema. This progresses to the 
development of new vessels on the retina. Although the early stages of diabetic 
retinopathy are asymptomatic, progression can result in significant visual 
impairment and without treatment will lead to blindness. (33) Currently nearly 3 
million people worldwide are blind as a result of diabetic retinopathy and it is the 
leading cause of blindness in people of working age in the western world. 
(33,34) In the UK alone there are 1280 new cases of blindness each year 
resulting from diabetic retinopathy. (35)  
A national diabetic eye screening programme was founded in the UK in 2004. 
From the age of 12 people with diabetes are invited to attend annual visits for 
digital retinal photography. Reports of the findings are sent to their GP to inform 
ongoing management or individuals are escalated to treatment if there have 
been sight-threatening changes. A report evaluating the service from 2004-14 
found that 79.3% of eligible individuals attended screening. Furthermore, over 
this time age-standardised prevalence of diabetic retinopathy remained stable 
(approximately 55%), and the prevalence of severe diabetic retinopathy halved 
to 10.35%. (31)     
Retinopathy is classified as background, pre-proliferative and proliferative, all 
with strict diagnostic criteria. Individuals progress through each stage, with 
proliferative retinopathy requiring treatment. Background retinopathy is defined 
as microaneurysms, retinal haemorrhages with or without exudate. Pre-
proliferative retinopathy is characterised by venous bleeding, venous loops or 
reduplication, intra-retinal microvascular abnormality, multiple deep, round or 
blot haemorrhages, and cotton wool spots. Proliferative retinopathy is 
diagnosed when there are new vessels, pre-retinal or vitreous haemorrhage, 
pre-retinal fibrosis with or without tractional retinal detachment. (35–38) A 
recent cohort study of 5000 people using the Welsh national screening service 
showed that 44% of people with type 1 diabetes had no diabetic eye changes, 
40% had background retinopathy, 8% had pre-proliferative retinopathy and 4% 
had proliferative retinopathy; the remaining 4% had maculopathy. (39) 
Laser photocoagulation is used for the treatment of proliferative retinopathy and 
maculopathy. (34) Laser light energy is directed at the retina which is absorbed 
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by the retinal pigments, heating the retina and resulting in thermal damage. It is 
used to treat sight-threatening retinopathy and has been shown to reduce the 
risk of both retinopathy progression and severe visual loss 12 months post-
treatment by approximately 50%. (33) 
Nephropathy 
Diabetic nephropathy is a common complication of type 1 diabetes. It is 
estimated to affect 40% of people with type 1 diabetes and substantially 
increases the risk of cardiovascular morbidity and mortality. (40) Chronic 
hyperglycaemia leads to damage and scaring of the glomerular vasculature. 
This damage is termed glomerulosclerosis and encompasses several defining 
features including; thickening of the glomerular basement membrane, 
microaneurysms, mesangial sclerosis, hyaline arteriosclerosis and mesangial 
node formation (Kimmelstiel-Wilson nodules). (32,40) These changes result in 
impaired blood flow to the kidney, hypertension, proteinuria and renal 
impairment. (41) Early recognition and intervention are key to reducing both 
morbidity and mortality.  
An early sign of diabetic nephropathy is microalbuminuria, with 7% of people 
diagnosed with type 1 diabetes already having microalbuminuria at the time of 
diagnosis. (40) Without intervention microalbuminuria progresses to 
macroalbuminuria, with progression reported in 30-45% of people with 
microalbuminuria. (40,42) Proteinuria (microalbuminuria or macroalbuminuria) is 
estimated to affect up to 40% of people with type 1 diabetes and has a peak 
incidence at 15-20 years disease duration. Eventually individuals develop renal 
failure and become reliant on renal replacement therapy or kidney transplant. 
Diabetic nephropathy is the leading cause of renal failure in developed 
countries. (32,40,43,44)  
Diagnosis of microalbuminuria and macroalbuminuria is made on the basis of 2 
out of 3 abnormal test results in a 3 to 6-month window. Traditionally 
microalbuminuria is defined as an albuminuria of 30-299mg/g on a spot urine 
sample and macroalbuminuria as albuminuria >300mg/g. (40) However, in 
order to allow for the dilution effect of urine, albuminuria can also be defined by 
albumin-creatinine ratio (ACR). Microalbuminuria is defined as an ACR >2.5 
mg/mmol in men and >3.5 mg/mmol in women, with macroalbuminuria >30 
mg/mmol. (45)  
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New guidance on diagnosis of diabetic nephropathy combines estimated 
glomerular filtration rate (eGFR) with ACR (Fig. 3). (3) eGFR should be routinely 
measured to monitor nephropathy progression as it provides the best estimate 
of overall measure of kidney function. Individuals with an eGFR <30 should be 
referred to a nephrologist. (40) 
 
 
Fig 3: NICE Classification of chronic kidney disease. Taken from Chronic kidney 
disease in adults: assessment and management guidance [CG182] (3) 
 
The mainstay of management for diabetic nephropathy is management of 
modifiable risk factors such as hyperglycaemia, hypertension and 
dyslipidaemia, alongside smoking cessation. (40) Renin-angiotensin system 
(RAS) blockade is also a key part of diabetic nephropathy management. RAS 
blockade reduces the risk of both nephropathy and cardiovascular disease 
through reducing blood pressure. This lowers intraglomerular pressure and 
reduces passage of proteins into the proximal tubule, resulting in a reduction in 
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albuminuria. Angiotensin-converting enzyme inhibitors (ACEi) have not only 
been shown to reduce the risk of microalbuminuria progressing to 
macroalbuminuria by 60%, but also make reversion to normoalbuminuric more 
likely. However, they should be prescribed with caution as use is 
contraindicated in patients with bilateral renal artery stenosis and during 
pregnancy, due to associated severe birth defects. (40,46) 
To minimise risk of nephropathy it is recommended that all people with type 1 
diabetes have an annual ACR recorded, aim to have a blood pressure 
<130/80mmHg, avoid a high-protein diet, and if they develop microalbuminuria 
be prescribed a RAS blockade. (20) In addition, those with nephropathy should 
be routinely assessed for coronary heart disease due to their vastly increased 
risk. (40)  
Neuropathy 
Diabetic neuropathy is a further microvascular complication. 10% of people with 
diabetes have neuropathy at diagnosis, this rises to 40-50% after 10 years. (47) 
The mechanism by which peripheral nerves are damaged is not currently 
understood but thought to be due to damage to small blood vessels. There are 
multiple manifestations including sensory /motor, focal/multifocal and 
autonomic. A distal symmetrical sensorimotor polyneuropathy is the most 
common diabetic neuropathy. This involves loss of sensation to light touch, 
vibration and temperature. This leaves individuals at risk of injury particularly to 
the foot and subsequent ulceration, with the potential to progress to amputation. 
(32) 
Macrovascular 
Chronic macrovascular complications of diabetes manifest as cardiovascular 
disease. This is the leading cause of death in people with diabetes and the 
largest expense in their care. Hypertension and hyperglycaemia lead to chronic 
injury and inflammation of both peripheral and coronary arterial walls. The 
resultant atherosclerosis increases risk of myocardial infarction along with 
elevating mortality rates from both ischaemic heart disease and cerebrovascular 
disease. (32) Macrovascular complications of diabetes are extensively reviewed 
elsewhere and were not studied during this Masters research.  
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2.2.3 Preventing development of complications  
Diabetic complication rates have improved, however, complication management 
remains the focus of diabetes care. (11,48,49) Maintaining good glycaemic 
control is consistently shown to be the most effective way of reducing incidence 
and progression of diabetic complications. (48,50) However, the risk of 
hypoglycaemia due to insulin therapy remains a barrier to tight control. (28,29) 
Whilst type 1 diabetes has historically been described as a disease that leads to 
total insulin deficiency, there is increasing evidence of variable beta cell loss 
following diagnosis. (2,8) Furthermore, studies have shown persistent low levels 
of endogenous insulin production in many people with type 1 diabetes, including 
those with long disease durations. (51–53) This is important as preserved 
endogenous insulin has been associated with reduced complication rates. 
(6,54,55) This has led to preservation of endogenous insulin production 
becoming the focus of immunotherapy trials. (56) 
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2.3 C-peptide 
2.3.1 What is C-peptide? 
C-peptide is produced in a 1:1 ratio with insulin during the cleavage of 
proinsulin. It was first discovered in 1967 and is the molecule adjoining insulin’s 
alpha and beta chains. (57) Processing of preproinsulin to proinsulin, followed 
by proinsulin to insulin and C-peptide, occurs within the beta cells of the islets of 
Langerhans in the pancreas. Preproinsulin is cleaved in the endoplasmic 
reticulum by signal peptidase to form proinsulin. Proinsulin folds to form 3 
disulphide bonds. Once folded proinsulin is transported through the Golgi 
complex into immature secretory granules, here cleavage of proinsulin occurs. 
(58,59) Cleavage is mediated by two endopeptidases working at separate sites, 
prohormone convertases 2 and 3. Intermediate molecules are produced due to 
loss of basic amino acids at each site via carboxypeptidase H. These 
intermediate molecules are termed des forms, des 31-32 split and des 64-65 
split, see Fig. 4. Following completion of cleavage at both sites, a single 
molecule of both insulin and C-peptide is produced. (4) The two molecules are 
stored in the secretory granules in beta cells ready for exocytosis, releasing 
insulin and C-peptide into systemic circulation. In healthy individuals plasma C-
peptide level is variable, reference ranges include 300-600pmol/l fasted and 
1000-3000pmol/l in the post-prandial state. (60,61) 
 
Fig. 4: Processing proinsulin to insulin. Taken from Temple et al.  (4,5) 
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2.3.2 A measure of endogenous insulin production 
C-peptide is the best measure of endogenous insulin production in insulin 
treated patients. C-peptide measurement allows measurement of endogenous 
insulin production whilst overcoming the barriers of measuring insulin directly. 
(62) All endogenous insulin produced initially travels through the portal venous 
system, with the liver responsible for regulating peripherally circulating levels. 
(63) First pass hepatic metabolism has been shown to extract 60-70% of 
endogenous insulin. (64) Moreover, hepatic clearance varies with physiological 
state, thus peripheral insulin does not necessarily reliably reflect endogenous 
insulin production. (65) In contrast, hepatic metabolism of C-peptide has been 
shown to be negligible. (66) C-peptide has a half-life of 20-30 minutes 
compared to insulin’s 3-5 minutes and slower metabolic clearance than insulin, 
4.5 vs 15 ml/min/kg. (66,67) With circulating levels 5 times greater than insulin 
and relatively low cross reactivity; it is a reliable, reproducible, practical 
alternative to determining endogenous insulin production. (66,68) Furthermore, 
it’s ultimate utility lies in its ability to differentiate between endogenous and 
exogenous insulin levels in those requiring exogenous insulin therapy. (66) This 
is because exogenous insulin treatment does not contain C-peptide.  
2.3.3 Measuring C-peptide 
C-peptide can be assessed in both in blood and urine. In the past there have 
been concerns regarding stability, however, provided it is collected correctly, C-
peptide is stable in EDTA plasma for 24-hours and urine in boric acid for 72-
hours at room temperature. Measurements can be taken fasting, randomly or 
following stimulation. C-peptide levels in blood are commonly reported in both 
nmol/l and pmol/l (1nmol/l = 1000pmol/l). In this thesis, where studies have 
reported in nmol/l levels have been converted to pmol/l to provide direct 
comparison with the results of our studies. Absolute deficiency is estimated as 
<80pmol/l when fasted in blood, <200pmol/l following stimulation in blood, and 
<0.2nmol/mmol following stimulation in urine. Stimulated serum C-peptide is 
commonly used as a reliable reproducible measure of C-peptide production. 
(66)  
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Stimulated and fasting measurements 
Stimulated measurements are the most precise, but fasting C-peptide does 
correlate well with stimulated C-peptide. (69) Clinical trials typically use a 
stimulated C-peptide measurement. (68) Beta cells can be stimulated to 
produce insulin using a number of tests, these include a mixed-meal tolerance 
test (MMTT), glucagon stimulation test (GST), oral glucose tolerance test, 
intravenous (IV) glucose tolerance test and arginine stimulation test (AST). 
MMTT’s and GST’s are commonly used in trial settings, with AST’s also being 
particularly sensitive. (70) Participants are fasted overnight for both the MMTT 
and GST. During the MMTT a liquid meal is ingested, and serum C-peptide 
measured at varying intervals for 2-4 hours. In comparison, the GST involves an 
IV glucagon injection with multiple serum C-peptide measurements for 10 
minutes. C-peptide classically peaks at 90 and 6 minutes in the tests 
respectively. (62,66) GST is associated with a higher number of adverse 
effects, the most common being nausea which Greenbaum et al. showed was 
experienced in 95% of 8-12 year olds.  Patients generally prefer the better 
tolerated MMTT despite it being more time consuming. Both are highly 
reproducible but the MMTT is more sensitive at 90 minutes than the GST at 6 
minutes. Thus, stimulated C-peptide measurement following a MMTT is 
established as the gold standard in type 1 diabetes trials. (62)  
A single C-peptide measurement 90-minutes following a MMTT provides a 
reliable estimate of beta cell function. (69) MMTT results are commonly 
analysed by assessing area under the curve at 120 minutes. (66) However, 
recently a single measurement at 90 minutes has been found to be both 
sensitive and specific for peak insulin secretion. Having a single sample taken is 
beneficial for both the patient and clinician, reducing the number of samples and 
duration of the test also reduces cost. This provides a practical alternative to a 
full MMTT. It was also shown that as a single measurement 90 minute C-
peptide following a MMTT was more reliable than a single fasting serum C-
peptide. (69) 
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Measuring C-peptide in urine 
C-peptide undergoes renal clearance, this occurs through catabolism and 
glomerular filtration. (60,71) Approximately 5% of C-peptide is excreted 
unchanged in urine. (66) C-peptide can be measured following a 24-hour urine 
collection. However, by utilising urinary C-peptide creatinine ratio (UCPCR) a 
single urine sample can be used. (66)  UCPCR provides both a reliable and 
reproducible measurement and has the benefit of being efficient and non-
invasive. (72) However, as it is renally excreted urinary C-peptide measurement 
is not validated in those with renal impairment. (73) Stimulated UCPCR 2 hours 
after a meal is highly correlated with MMTT 90 minute C-peptide. (53,66) The 
test can be carried out at home and is stable for 72 hours allowing time for 
transport and analysis. UCPCR comes with a number of cautions. It is a less 
precise test and has a different normal range to serum C-peptide making cross 
comparison difficult. Whilst not as accurate, stimulated UCPCR provides a very 
practical, non-invasive, inexpensive alternative to MMTT 90 minute serum C-
peptide. (73)  
2.3.4 New information - C-peptide assay development 
The development of ultra-sensitive assays has allowed for detection of C-
peptide at very low and previously undetectable levels. Until recently, C-peptide 
assays have been restricted by lower limits of detection around 30pmol/l. (52) 
However, newly developed isotopic assays utilising monoclonal antibodies have 
been found to be both sensitive and specific. Roche’s 
electrochemiluminescence immunoassay offers a limit of detection of 3.3pmol/l 
with Mercodia’s ultrasensitive ELISA pushing the limit of detection to 1.5 pmol/l. 
(51,52) Due to a variety of assays and units used, lack of standardisation 
makes results potentially incomparable and they should be interpreted with 
caution. (66) However, both assays have demonstrated the ability to identify 
significant numbers of individuals with persistent C-peptide that would have 
been previously undetectable.(51,53) Currently there is evidence to suggest 
that despite the ELISA having a lower limit Roche offer a more sensitive test. 
(51,52) 
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2.3.5 C-peptide as an Outcome Measure 
Research has looked to the potential benefit of prolonging C-peptide production. 
A number of immunotherapy trials have looked to prevent, delay or even 
reverse diabetes development. Trials typically focus on groups at high risk of 
developing type 1 diabetes or those with newly diagnosed diabetes. While there 
are no current studies that have been able to demonstrate a prolonged impact, 
there have been a number showing some degree of short term success. This 
provides both hope and direction for future research. C-peptide is a key primary 
outcome in immunotherapy trials. (56) 
C-peptide has been selected as a primary outcome in intervention trials 
because it reflects underlying beta cell function. Declining beta cell function is 
the key pathophysiological process in the development of diabetes. Thus, 
preservation of beta cells is intrinsic to disease prevention and is the focus of 
many immune therapy and intervention trials. (68)  In contrast to autoantibodies, 
which can be present for a number of years prior to disease development, C-
peptide is a good measure of an individual’s current disease status. (66) It is a 
direct measure of endogenous insulin production with reproducible results that 
can be reliably monitored over time. Therefore, C-peptide is the most 
appropriate primary outcome in intervention studies focusing on beta cell 
function. (68) Evidence regarding the utility of C-peptide comes from two key 
areas, The Diabetes Control and Complications Trial and islet cell 
transplantation studies. (54,74) 
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2.4 Clinical benefits associated with preserved 
C-peptide 
2.4.1 Diabetes Control and Complications Trial (DCCT) 
The DCCT, a landmark trial in type 1 diabetes, revealed that intensive treatment 
was paramount to reducing complications. This was a large scale randomised 
control trial across 29 centres comparing intensive and conventional therapy in 
type 1 diabetes. It assessed primary and secondary prevention of micro and 
macrovascular complications and risk of severe hypoglycaemia. The 1441 
participants with diabetes duration 1-15 years were followed for an average of 
6.5 years. The trial concluded that intensive insulin therapy was significantly 
superior in both preventing and delaying progression of microvascular 
complications when compared to conventional treatment. (50,54,75) 
Furthermore, approximately 30 year follow up showed that those who had 
received intensive treatment had a lower risk of mortality compared to the 
people who had received conventional therapy (absolute risk reduction 1/1000 
patient years). (76) The lessons learnt from the DCCT have greatly influenced 
treatment standards today.  
Intensive therapy aimed to maintain normal glycaemic levels. It involved 3-4 
insulin injections per day or use of an insulin pump. Blood glucose was checked 
at least four times each day and insulin dose adjusted accordingly. Individuals 
checked their 3am blood glucose weekly and focused on both diet and exercise. 
Comprehensive supervision and support was given through monthly clinic visits 
and telephone contact for troubleshooting. In contrast, conventional treatment 
involved 1-2 insulin injections each day and once daily blood or urine glucose 
checks. Initial dietary advice was provided and participants attended clinics 
every three months. (54)  
The role of intensive therapy in prolonging endogenous insulin production was 
also investigated in a restricted cohort with short disease duration. Screening of 
over 3000 individuals identified 855 people with short duration type 1 diabetes 
(<5 years) aged 13-39 with a stimulated C-peptide ≤500pmol/l. The cohort was 
divided into C-peptide responders (200-500pmol/l) and non-responders 
(<200pmol/l). Individuals were then randomly allocated intensive or 
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conventional therapy. There were 303 responders (138 intensive treatment, 165 
conventional treatment) and 552 non-responders (274 intensive treatment, 278 
conventional treatment). Stimulated C-peptide was assessed annually for up to 
6 years or to the point C-peptide fell below 200pmol/l. (54) A limitation of the 
DCCT was the selective exclusion of people with higher levels of endogenous 
insulin (>500pmol/l within the first 5 years of diagnosis, and >200pmol/l after 
this point). This was by design to excluded non-type 1 diabetes cases, but also 
limited the ability to study the full impact of preserved C-peptide.  
Initial analysis of this group of participants showed intensive treatment resulted 
in improved outcomes regardless of C-peptide response, in line with the 
findings of the main study. The intensively treated achieved better glycaemic 
control with a consistently lower HbA1c. However, this came at the cost of 
higher rates of severe hypoglycaemia. Among responders, retinopathy and 
microalbuminuria were less likely to occur when intensively treated, and when 
present, were slower to deteriorate. This was attributed to their lower HbA1c. 
Intensive treatment also significantly slowed loss of beta cell function, with 
responders maintaining higher C-peptide levels for longer. These findings 
illustrated intensive treatment was integral to good diabetes management and 
reducing complications. (54) 
C-peptide responders benefited from reduced complications when intensively 
treated, but not with conventional treatment. Within the intensively treated 
group, responders had a lower HbA1C, risk of retinopathy and microalbuminuria 
progression and 65% reduction in risk of severe hypoglycaemia compared to 
non-responders. However, these differences were not reflected in the 
conventionally treated group, where responders and non-responders had 
similar HbA1c, risk of retinopathy progression and microalbuminuria 
development. This suggested that the benefit of C-peptide could only be utilized 
when intensively treated. (54) 
Further analysis showed that higher levels of C-peptide reduced the incidence 
of retinopathy, nephropathy. Steffes et al. divided C-peptide response into four 
groups; undetectable (≤30pmol/l), minimal (40-200pmol/l), baseline only 
(>200pmol/l at baseline but subsequently <200pmol/l) and sustained (210-
500pmol/l at baseline and at least the first annual visit). In the intensively 
treated group the rate of deterioration in retinopathy and nephropathy was 
35 
 
significantly lower in those with detectable C-peptide compared to those with 
undetectable levels. However, a key finding was that rates of both complications 
decreased according to C-peptide group, favouring C-peptide production. 
Similar results were seen in the conventionally treated group. (6) 
Sustained levels of C-peptide reduced hypoglycaemia rates despite intensive 
treatment. Overall the intensive group were found to have higher rates of 
hypoglycaemia than the conventionally treated group. However, those with 
sustained levels of C-peptide had a lower rate and prevalence of 
hypoglycaemia than the other three intensively treated groups. Interestingly, 
their hypoglycaemia rate was considerably more similar to those in the 
conventionally treated group, see Fig. 5. This suggests the possibility that in 
those with sustained C-peptide levels intensive therapy may be utilised to 
minimise microvascular complications whilst endogenous insulin protects from 
hypoglycaemia. In addition, these findings propose that a C-peptide of 
200pmol/l is a clinically significant value. (6)  
 
Fig. 5: “First occurrence of hypoglycaemia during the first 6 years of the DCCT, 
by stimulated C-peptide and treatment group”. Taken from Steffes et al.  (6) 
A subsequent analysis of the intensive group by Lachin et al. echoed these 
findings.  Using C-peptide as a continuous variable they demonstrated an 
approximately linear association with HbA1c, insulin dose and rate of 
hypoglycaemia. There was a strong association between decreasing C-peptide 
and retinopathy deterioration. This study further strengthened the evidence of 
the positive impact of persistent C-peptide with intensive treatment and 
highlighted the potential importance of even small differences in C-peptide. (55) 
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2.4.2 Islet Cell Transplant 
The DCCT provided evidence on the impact of C-peptide in a cohort close to 
diagnosis (<5 years duration). In contrast, islet cell transplantation (ICT) studies 
can be used to assess the impact of C-peptide in individuals with advanced 
diabetes and absolute insulin deficiency. ICT provides a unique opportunity to 
investigate the impact of restoring C-peptide production in an individual.  
C-peptide is used as a key outcome measure in islet cell transplantation. ICT is 
used when individuals experience recurrent life-threatening hypoglycaemia. An 
NHS funded national ICT service was commissioned in 2008 with aims to 
reduce insulin dose, HbA1c and rate of hypoglycaemia. Numbers of successful 
outcomes continue to rise but it is a complex and costly service. C-peptide is 
used to define graft survival. (77,78) 
Data from ICT patients showed that increased levels of C-peptide reduced 
hypoglycaemia and improved glycaemic control. Brooks et al. analysed data 
from ICT recipients from the first 3 years of the service. A stimulated C-peptide 
>50pmol/l was used to define a functioning graft post-transplant, with all 
recipients having been C-peptide negative prior to transplant. At an average of 
24 (13.5-36) months post-transplant, 80% of recipients had preserved graft 
function. Hypoglycaemia rates had fallen from 20 to 0.3 episodes per patient 
year (p<0.001) and 70% maintained an HbA1c <7.0%. This study showed that 
an increase in C-peptide in those that were previously C-peptide negative 
results in reduction of hypoglycaemia and HbA1c, along with reducing insulin 
dose and hypoglycaemic awareness. (77) 
Higher levels of C-peptide in ICT recipients result in greater reductions of 
hypoglycaemic risk and improvements in glycaemic variability. 12 ICT recipients 
were monitored throughout their first 18 months post-transplant. Stimulated C-
peptide response was categorised as low (<200pmol/l), moderate (200-
500pmol/l), good (500-1000pmol/l) and excellent (>1000pmol/l). Analysis was 
stratified by C-peptide group. Higher C-peptide response was shown to 
decrease HbA1c and insulin dose. It also reduced the risk and duration of both 
hyperglycaemia and hypoglycaemia, as measured by CGM. CGM also 
evidenced a strong continuous association between increasing C-peptide and 
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reduction in glucose variability. This further supports the evidence that minute 
changes in C-peptide have the potential to be advantageous. (79) 
Additional islet transplant research suggests that achieving higher C-peptide 
levels slows deterioration of microvascular complications. A crossover study 
assessing progression of microvascular complications compared intensive 
insulin treatment to ICT. It involved 45 participants with type 1 diabetes and 
undetectable C-peptide. Initially participants received intensive insulin therapy 
and then progressed to ICT when a donor became available. Both retinopathy 
and GFR were found to progress significantly slower following ICT and there 
was no statistically significant difference in progression of neuropathy.  It is 
proposed that ICT is associated with higher C-peptide response than intensive 
treatment and thus better glycaemic control. This supports the relationship 
between higher C-peptide and slower complication progression. (80)  
Increased beta cell function is associated with improved mean blood glucose. 
ICT recipients underwent 72-hour CGM prior to and at 3, 6, 9, 12, 24 and 36 
months following transplantation. Graft function was assessed by beta-score 
which incorporates C-peptide, HbA1c, blood glucose and current treatment. A 
key finding of the study was that better graft function was correlated with lower 
mean blood glucose.  Mean glucose itself is an independent predictor of long-
term cardiovascular risk. As such, increasing C-peptide may have the ability to 
improve blood glucose and in turn reduce mortality resulting from 
cardiovascular disease. (81) 
Sustained C-peptide production following whole pancreas transplant has been 
shown to reverse diabetic complications. Selected pancreatic transplant 
recipients with lesions of diabetic nephropathy, who remained insulin 
independent at 10 years post-transplant, were seen to have substantial reversal 
of nephropathy 10 years post-transplant. This was ascribed to a significant 
duration of euglycaemia. Renal biopsies were taken before transplant and at 5 
and 10 years post-transplant. Biopsies at 10 years showed significantly reduced 
thickness of both the glomerular and tubular basement membranes from 
baseline (p<0.001 and p=0.004 respectively), among other improved biopsy 
measures. (82) A further study assessing neuropathy five years post-ICT 
showed that increased C-peptide was associated with improvement in sensory 
nerve conduction velocity and action potentials. However, motor nerve 
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conduction velocity and cardiac autonomic neuropathy showed no significant 
change. (83) This suggests that persistent C-peptide production not only 
reduces risk of complication progression, but it is potentially hugely beneficial in 
reversal of complications.  
ICT studies have highlighted the potential for improvement of hypoglycaemia 
with C-peptide restoration showing that restoring C-peptide production improves 
hypoglycaemic awareness and rate alongside reducing glucose variability. 
(77,79) In addition, some studies have hinted at the improvement of 
microvascular complications with increasing C-peptide. (80,82,83) However, 
evidence from ICT is limited to studies of relatively short duration. There would 
be great benefit in future studies assessing the long-term effect of C-peptide 
restoration on hypoglycaemia and microvascular complications.    
2.4.3 Long duration evidence  
C-peptide preservation in long duration type 1 diabetes 
As many as 80% of people with long duration type 1 diabetes have detectable 
C-peptide. Lower limits of detection have enabled identification of C-peptide 
preservation in those with long duration type 1 diabetes. Evidence from 
stimulated C-peptide data showed that 73% of people with duration >5years 
had detectable serum C-peptide following a MMTT, with 20% showing levels 
>200pmol/l. Absolute C-peptide response was shown to decline with increasing 
duration. Despite this 68% of those with a type 1 diabetes duration >30years 
had detectable C-peptide. This suggests that C-peptide decline occurs over a 
number of decades rather than rapidly like previously thought. Furthermore, C-
peptide positive participants had durations comparable to their C-peptide 
negative counterparts, suggesting additional influencing factors. Findings were 
replicated within the cohort using stimulated UCPCR which showed that 69% 
had preserved C-peptide production. This provides irrefutable evidence that C-
peptide production can be preserved in long duration type 1 diabetes with large 
numbers proven to be C-peptide microsecretors.  (52) 
Multiple studies have supported the finding of preserved C-peptide production in 
long duration diabetes. Wang et al. used fasting C-peptide to show that 43% of 
those with mean duration of 19.4 years have detectable C-peptide. (51) 
Furthermore, Keenan et al. focused on extreme diabetes duration in 411 Joslin 
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Medallist’s (all with duration >50years). 67.4% had detectable random C-
peptide, with 64.4% having C-peptide 30-200pmol/l and 2.6% ≥200pmol/l. The 
higher C-peptide group were significantly older at diagnosis and had an 
associated lower HbA1c. (84) Supporting evidence was provided by a large 
population based study (n=924) that assessed C-peptide response using 
stimulated UCPCR following a meal at home in people with duration >5years. 
They showed that 52% had detectable C-peptide, with 8% >0.2nmol/mmol. 
Interestingly, they found that the likelihood of having a result >0.2nmol/mmol 
increased by 8% for each year older an individual was at diagnosis and 
decreased by 4% for each additional year of duration. (53) 
Functioning beta cells in long duration type 1 diabetes 
In the majority of people with type 1 diabetes, C-peptide levels respond to a 
stimulus, indicating functioning beta cells. This has been shown through a 
comparison between fasting and stimulated C-peptide in 74 participants with 
type 1 diabetes duration >5years. 54 individuals were shown to have detectable 
C-peptide (>3.3pmol/l) with 80% showing an increase in C-peptide response 
following a MMTT, 11% showing no change and no participants showing a C-
peptide reduction. This shows that in long duration diabetes beta cell function is 
preserved. (52) 
Beta cell function is preserved in those with diabetes duration >50 years. 
Research assessing extreme diabetes duration showed that 42% (n=13) of 
Joslin Medallists with random C-peptide >100pmol/l were able to at least double 
their fasting C-peptide in response to a MMTT. Moreover, a random C-peptide 
≥200pmol/l significantly increased the chance of doubling C-peptide in response 
to the MMTT. This supports evidence that beta cell function remains in extreme 
diabetes duration, and suggests that preserved function may play a protective 
role. (84) 
Further evidence shows that hyperglycaemia is associated with a higher C-
peptide levels in long duration diabetes. Analysis of weekly fasting serum C-
peptide in 4 individuals for 14 weeks showed that hyperglycaemic samples 
(>150mg/dl) were associated with higher levels of C-peptide than euglycaemic 
(<150mg/dl). Additional analysis of 3 of these individuals including non-fasting 
C-peptide results showed a linear association between glycaemic level and 
serum C-peptide. Throughout the wider cohort (n=182, mean duration 19.4 
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years) results from a single fasting C-peptide were stratified into well-defined C-
peptide ranges. Where C-peptide was detectable (>1.5pmol/l) hyperglycaemic 
individuals had significantly higher levels. This further strengthens the evidence 
that even exceptionally low C-peptide levels (median 1.5pmol/l) have favourable 
effects and indicates functioning beta cells in long duration type 1 diabetes. (51) 
Histological evidence 
Evidence from pancreatic histology further supports beta cell function in those 
with long duration type 1 diabetes. Historically it was thought that type 1 
diabetes resulted in total beta cell destruction. However, a number of studies 
have shown that insulin containing cells can be found in the pancreas of those 
with long duration type 1 diabetes. (84–87) Evidence from a 2005 study 
analysed pancreatic sections from 42 individuals with type 1 diabetes. It 
confirmed presence of beta cells in 88% of individuals regardless of duration 
(range 7-67 years). (85) Gianani et al. also studied the pancreases of those with 
childhood onset type 1 diabetes (mean duration 14 years) but found the majority 
of pancreases to be insulin deficient. Despite this they identified two distinct 
patterns of beta cell survival. The first exhibited lobular areas of abnormally 
functioning beta cells and the second showed beta cells present in all islets but 
with numbers consistently reduced throughout. (86) 
Functioning beta cells were identified in pancreases of those with extreme 
duration diabetes. Keenan et al. studied 9 Joslin Medallist’s pancreases and 
made comparisons with data collected during life. All pancreases studied 
showed insulin positive cells. However, in those diagnosed <8 years old (n=7) 
the majority of islets were atrophic with no insulin staining. In contrast, the 
remaining two medallists (onset aged 23 and 30) had a mix of insulin deficient 
and insulin positive islets. They also had both at least doubled their fasting C-
peptide in response to a MMTT, indicating the potential advantage of older age 
of onset in maintaining endogenous insulin production. This study also 
demonstrated a notable correlation between C-peptide at MMTT and number of 
beta cells found post-mortem. When comparing Medallists with a random C-
peptide ≥200pmol/l to individuals without diabetes, the Medallists had MMTT 
stimulated C-peptide 80-90% lower than individuals without diabetes. This 
difference was reflected in the proportion of functional beta cells found post-
mortem when comparing the two groups. A similar relationship was seen in 
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those that had been unable to double their fasting C-peptide following MMTT, 
both their MMTT C-peptide level and number of functional beta cells were 
approximately 2-3% of controls without diabetes. The unique information 
provided by this cohort with extreme diabetes duration supports evidence that 
functioning beta cells can be preserved in long duration type 1 diabetes. (84) 
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2.5 There remains a deficiency in evidence of 
the clinical impact of preserved C-peptide in 
long duration type 1 diabetes 
 
Evidence regarding the relationship between C-peptide and diabetes 
complications is limited by being almost exclusively from the DCCT and based 
on C-peptide relatively close to diagnosis. Lessons learnt from the DCCT 
undoubtedly reshaped the management of type 1 diabetes, definitively showing 
that intensive treatment was superior. However, the majority of evidence for the 
benefit of persistent C-peptide production comes from three analyses of the 
same data with a focus on short duration diabetes. Furthermore, the DCCT took 
place more than 30 years ago and since then management of diabetes, and 
particularly its complications, has improved drastically. Improvements in C-
peptide measurement could allow replication of these findings in long duration 
diabetes or at even lower levels of C-peptide.  
It has been established that persistent low levels of C-peptide are common in 
long duration type 1 diabetes. Currently there is very little evidence regarding 
the benefit of persistent C-peptide on complications in long-duration diabetes. 
This is despite long-term preservation of C-peptide being a key goal in 
intervention trials. This highlights a paucity of evidence and an area in need of 
future research.  
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Introduction part 3: Glucagon 
dysregulation in type 1 
diabetes 
  
44 
 
3.1 Glucagon dysregulation in type 1 diabetes 
 
Ordinarily alpha cells (α) secrete glucagon to work in conjunction with beta cells 
(β) to maintain glucose homeostasis and prevent hypoglycaemia. However, in 
type 1 diabetes there is evidence of glucagon dysregulation. Hypoglycaemic 
clamp studies show inadequate glucagon secretion during hypoglycaemia. (88) 
Whilst studies assessing glucagon following a meal have demonstrated 
inappropriate production. (89–92) 
One possible explanation is that endogenous insulin regulates glucagon 
production, with falling endogenous insulin levels triggering glucagon release. 
This regulatory effect is lost in those with type 1 diabetes. (7) Glucagon 
production becomes reliant on glucose, with inappropriate secretion of glucagon 
in response to a rise in glucose (Fig. 6). Evidence supporting the regulatory role 
of endogenous insulin comes from declining C-peptide levels being associated 
with increasingly dysregulated glucagon. (89)  
 
 
Fig.6: Physiology and pathophysiology in type 1 diabetes of alpha and beta cell 
function. Taken from Cryer 2011. (7) 
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Further evidence comes from islet cell transplantation studies using 
hypoglycaemic clamps. Prior to transplant glucagon levels during 
hypoglycaemia were comparable with those at euglycaemia. However, at both 6 
and 18 months post-transplant, glucagon levels moderately increased in 
response to hypoglycaemia; although not to the level of controls without 
diabetes. This demonstrates that restoration of endogenous insulin production 
is associated with a striking improvement in glucagon regulation. However, 
these results must be interpreted with caution as transplanted α-cells are likely 
to influence glucagon levels. (93,94)  
Currently research into the regulatory role of endogenous insulin is restricted to 
relatively few studies. Until recently the lack of a reliable glucagon assay 
remained a limiting factor. (95) Additionally, evidence for the relationship 
between glucagon and hypoglycaemia in type 1 diabetes has been limited to 
relatively few hypoglycaemic clamp studies, with nobody robustly investigating 
the relationship between meal stimulated glucagon and hypoglycaemia in long 
duration diabetes. 
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Chapter 2: Methods 
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The TIGI study 
 
The TIGI (Type 1 Diabetes, Immunology, Genetics and endogenous Insulin 
production) study is a cross-sectional case-control study carried out in the 
South West of England (NCT03490773). It aims to assess the genetic and 
immunological predictors of endogenous insulin production in a long duration 
type 1 diabetes cohort. All participants completed a MMTT and hypoglycaemia 
questionnaires were collected as a secondary outcome. While immune 
analyses continue, hypoglycaemia outcomes are able to be reported.  
Study participants  
Potential TIGI participants were identified from the existing UNITED (Using 
pharmacogeNetics to Improve Treatment in Early onset Diabetes) study cohort 
(NCT01238380). The UNITED study was a population-based study recruiting 
participants from the Tayside and Exeter areas. The UNITED study recruited 
individuals with type 1 diabetes diagnosed before the age of 30 who were under 
the age of 50 at recruitment. They recorded a meal stimulated urine C-peptide-
creatinine ratio (UCPCR) in all participants. (53) 
TIGI participants were selected from the UNITED study with the aim of forming 
high and low C-peptide groups. Potential participants had to have >5 years 
disease duration and be in the top or bottom quintile of UCPCR adjusted for 
their duration. Additional inclusion criteria were a clinical diagnosis of type 1 
diabetes, insulin treatment from diagnosis, 5-65 years old at recruitment 
(inclusive) and ability to provide consent. Exclusion criteria included pregnancy 
or lactation, history of infectious illness within the previous 2 weeks, use of 
steroids or immunosuppression medications, having immunoglobulin treatments 
or blood products in the previous 3 months, any medical condition that would 
impact patient safety, recreational drug or alcohol abuse and severe diabetes 
complications.  
Young onset type 2 diabetes and monogenic diabetes were robustly excluded 
from the TIGI cohort. All participants with UCPCR >0.2nmol/mmol underwent 
autoantibody testing (GAD and IA2). Those that were antibody negative with a 
BMI >30 kgm-2 were excluded to avoid inclusion of young onset type 2 diabetes. 
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Participants with monogenic diabetes were excluded by genetically testing 
potential participants with UCPCR >0.2nmol/mmol and negative antibodies, as 
previously described. (2,53,96)  
All remaining 221 participants attended a single study visit where C-peptide 
status was confirmed using a MMTT. All TIGI participants provided informed 
consent and the National Research Ethics Service Committee South West 
approved the study (13/SW/0312). 
Study visit 
Most participants visited the National Institute for Health Research (NIHR) 
Exeter Clinical Research Facility (CRF). A study nurse visited participants at 
home if they could not attend the CRF. Baseline data was collected on all 
participants, this included height, weight, age of diagnosis, previous and current 
insulin treatment and family history of diabetes. Participants were also asked to 
complete a modified Clarke/Edinburgh hypoglycaemia questionnaire comprised 
of both the Clarke and Gold hypoglycaemia questionnaires. (97,98) 
All participants completed a standard MMTT. (62) Participants ingested 160ml 
of Fortisip Compact, Nutricia, UK. This consists of 240kcal, 9.6g protein, 9.3g 
fat and 29.7g carbohydrate per 100ml. Participants attending the CRF 
completed a multiple time point MMTT with blood samples taken at 0, 30, 60, 90 
and 120 minutes. Those who were visited at home and/or under the age of 16 
had an abbreviated MMTT where samples were taken at 0 and 90 minutes.  
Blood samples taken were analysed for peripheral blood mononuclear cells, 
DNA extraction, and serum C-peptide among other routine biomarkers including 
HbA1c. C-peptide and glucose were measured at all time points. Proinsulin and 
glucagon were measured both fasting and at 90 minutes.  
C-peptide at 90 minutes following MMTT was used as the C-peptide measure 
for analysis. (62,69)  For grouped analysis 90-minute C-peptide was used to 
confirm C-peptide group as either preserved (>20pmol/l) or low (<10pmol/l), to 
ensure participants remained in the pre-defined groups.  
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Key assay’s 
 
Both C-peptide and glucagon analyses were carried out at the Clinical 
Chemistry Department at the Royal Devon and Exeter NHS Foundation Trust, 
Exeter, UK. 
C-peptide assay 
Serum C-peptide was analysed on the Roche E170 analyser (Roche 
Diagnostics, Mannheim, Germany). The assay used a direct 
electrochemiluminescence immunoassay utilising mouse monoclonal anti-C-
peptide antibody labelled with ruthenium and a second mouse monoclonal anti-
C-peptide antibody coupled to paramagnetic particles. The limit of detection of 
the assay is 3.3pmol/l. C-peptide assays are standardised against The World 
Health Organisation International Standards 84/510. (99) 
Glucagon assay 
Glucagon was measured using the Mercodia (Mercodia, Uppsala, Sweden) 
Glucagon ELISA, measured on the Dynex D2 ELISA (Dynex, Lincoln, UK). The 
limit of detection for this assay is 1.5pmol/l.  
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Modified Clarke/Edinburgh hypoglycaemia 
questionnaire 
 
Participants were asked to complete a modified Clarke/Edinburgh 
hypoglycaemia questionnaire, see appendix. This is comprised of Clarke’s 
hypoglycaemia questionnaire with the addition of the Gold score for impaired 
hypoglycaemia awareness. (97,98,100) This was added to the TIGI study 
protocol after the initial recruitment phase, as such it is a secondary outcome 
available in a subset of TIGI study participants.  
Clarke’s hypoglycaemia questionnaire 
Clarke’s hypoglycaemia questionnaire can be used to assess both impaired 
hypoglycaemic awareness and rate of hypoglycaemia. It is a multiple choice 
questionnaire made up of 8 questions with a maximum score of 7. It asks about 
both moderate and severe hypoglycaemia, along with frequency of 
hypoglycaemia and perceived hypoglycaemic awareness. Each multiple choice 
answer is defined as either reduced awareness (1 point) or aware (0 points). 
Selection of a reduced awareness answer for questions 1-4 and 7-8 scores the 
participant a point. An additional point is gained when the answer to question 5 
is less than the answer to question 6. A score ≥4 indicates reduced 
hypoglycaemic awareness and ≤2 indicates awareness, with a score of 3 a 
middle ground. (97,100) 
Self-reported hypoglycaemia rate can also be calculated using Clarke’s 
hypoglycaemia questionnaire using responses to questions 5 and 6. These 
questions ask how many times in the last month participants have had a blood 
glucose <3.5mmol/l with and without symptoms respectively. Monthly 
symptomatic and asymptomatic hypoglycaemia rates can then be estimated 
from the participants answer. “Never” is recorded as 0; “1-3 times” as 2; “1 time 
per week” as 4 (1x4); “2-3 times per week” as 10 (2.5x4); “4-5 times per week” 
as 18 (4.5x4); and “almost daily” as 25. Symptomatic and asymptomatic rates 
can be combined to provide an overall monthly rate of hypoglycaemia. (101) 
The Clarke score estimated impaired hypoglycaemic awareness to be 26% in a 
type 1 diabetes cohort. This is consistent with other studies on prevalence of 
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impaired hypoglycaemic awareness. (102) Furthermore, its use has been 
validated using hypoglycaemic clamps, with 66.7% sensitivity and 85.7% 
specificity for impaired hypoglycaemia awareness. (103)  
Gold score for impaired awareness of hypoglycaemia 
The Gold score assesses hypoglycaemic awareness using a Likert scale (1-7). 
Asking participants score the extent to which they feel particular hypoglycaemic 
symptoms during a day time episode of hypoglycaemia, from “not present” to 
“present a great deal”. Symptoms are divided into autonomic, neuroglycopenic 
and non-specific. The questionnaire also asks participants to score their 
hypoglycaemic awareness (1-7), from “always aware” to “never aware”. 
Reduced awareness is defined as a total score ≥4. Reduced hypoglycaemic 
awareness as defined by the Gold score has been shown to be highly 
concordant with reduced awareness in the adult population. In addition, it 
correlates well with impaired hypoglycaemic awareness as defined by Clarke’s 
hypoglycaemia questionnaire (Spearman’s rho = 0.868, p=0.001). (98,100,102)  
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Abstract 
Aims 
Most people with type 1 diabetes have low levels of persistent endogenous 
insulin production. The Diabetes Control and Complications Trial showed that 
close to diagnosis preserved endogenous insulin was associated with lower 
HbA1c, hypoglycaemia and complication rates, when intensively treated. We 
aimed to assess the clinical impact of persistent C-peptide on rate of 
hypoglycaemia and HbA1c in those with long duration (>5years) type 1 
diabetes.  
Methods 
We conducted a cross-sectional case-control study of 221 people with type 1 
diabetes. We confirmed ongoing endogenous insulin secretion by measuring C-
peptide after a mixed-meal tolerance-test. We compared self-reported 
hypoglycaemia, HbA1c, insulin dose and microvascular complications in those 
with preserved and low C-peptide.  
Results 
Stimulated median (IQR) C-peptide was 114pmol/l (43, 273) and <3pmol/l (<3, 
<3) in those with preserved and low C-peptide respectively. Participants with 
preserved C-peptide had lower reported monthly rates of hypoglycaemia, with 
21% fewer symptomatic episodes, 5.9 vs 7.5 (incidence rate ratio (IRR) 0.79, 
p=0.001); and 65% fewer asymptomatic episodes, 1.0 vs 2.9 (IRR 0.35, 
p<0.001). Those with preserved C-peptide had a lower insulin dose (0.68 vs 
0.81 units/kg, p=0.01) but similar HbA1c (preserved 69 vs low 67mmol/mol, 
p=0.06).  
Conclusions 
Patients with type 1 diabetes and preserved endogenous insulin production 
receiving usual care in the UK have lower daily insulin doses and fewer 
hypoglycaemic episodes, but no difference in HbA1c. This is consistent with 
non-intensive treatment in previous studies, and suggests a need for therapy 
intensification to gain full benefit of preserved endogenous insulin.  
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Introduction 
Recent work has shown that many individuals with long duration type 1 diabetes 
continue to produce low levels of endogenous insulin, however, the clinical 
significance of this is uncertain. Beta cell function declines with increasing 
disease duration in type 1 diabetes and this was assumed to progress to total 
beta cell loss. (8) Recent studies have demonstrated persistent endogenous 
insulin in many people with long duration type 1 diabetes. (51–53,68,104) Whilst 
there is rapid initial decline post diagnosis, insulin secretion reaches a plateau 
after approximately 7 years post diagnosis. (2) Using highly sensitive C-peptide 
assays up to 80% of those with long duration type 1 diabetes (median duration 
18 years) have been shown to have low level, detectable endogenous insulin 
secretion. (53) Furthermore, some people with long duration type 1 diabetes 
have surprisingly high levels of endogenous insulin, with 8-15% of people 
diagnosed in adulthood having either a serum C-peptide >200pmol/l or a urine 
C-peptide creatinine ratio of >0.2nmol/mmol. (53,104) The strongest clinical 
associations of C-peptide appear to be disease duration and age of diagnosis, 
with those diagnosed younger being much less likely to have persistent C-
peptide. (53,68,104,105) 
The Diabetes Control and Complications Trial (DCCT) and islet cell transplant 
studies have provided evidence for the clinical significance of persistent C-
peptide. Grouped and continuous prospective analyses of the DCCT showed 
higher C-peptide levels were associated with lower insulin dose, improved 
glycaemic control, fewer microvascular complications and markedly lower rates 
of hypoglycaemia. (6,54,55) These findings were only seen in the intensively 
treated arm of the DCCT, where among intensively treated participants 
persistent postprandial blood C-peptide >200pmol/l was associated with a 
reduction in HbA1c and a 65% risk reduction in severe hypoglycaemia when 
compared to those with C-peptide <200pmol/l. (54) Findings from the DCCT 
highlight that the benefit of persistent C-peptide may arise from allowing tighter 
glucose control with intensive treatment through protection from hypoglycaemia. 
Additional data from Islet transplant recipients reveal that restoration of even 
partial beta cell function improves glycaemic control, variability and 
hypoglycaemic awareness along with reducing rates of hypoglycaemia. (77–
79,81,106) The effects of improved beta cell function in islet transplantation 
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appear continuous and not linked to an absolute threshold, with hypoglycaemic 
episodes in particular often improving with minimal graft function. (79) These 
results are important evidence for international efforts to prevent or reverse beta 
cell loss. (107) While the DCCT provides clear evidence of benefit from 
preserved endogenous insulin secretion in an intensively treated trial setting, 
and studies of islet cell transplants show the clear benefit of restoring relatively 
large amounts of endogenous insulin secretion, the impact of preserved 
endogenous insulin in patients with longstanding diabetes receiving usual 
clinical care is unclear. 
We aimed to assess the clinical impact of preserved endogenous insulin 
secretion, measured using C-peptide, in patients with long duration type 1 
diabetes. 
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Methods 
The TIGI (Type 1 diabetes, Immunology, Genetics and endogenous Insulin 
production) study is a cross sectional, observational case-control study of 
people with long duration type 1 diabetes in the UK. (2) We recruited 
participants from the cross sectional UNITED (Using pharmacogeNetics to 
Improve Treatment in Early onset Diabetes) study, a population based study of 
those diagnosed with diabetes before age 30 (and aged under 50 at 
recruitment). (53) Potential TIGI participants were selected on the basis of 
diabetes duration >5 years and being in either the top or bottom quintile of 
urinary C-peptide creatinine ratio (UCPCR) for their diabetes duration in 
UNITED(53). All patients included in TIGI had clinically defined type 1 diabetes 
diagnosed under the age of 30, were treated with insulin from diagnosis and 
lived in the South West of the UK. Those with renal impairment were excluded 
from the analysis as C-peptide is not a reliable measure of endogenous insulin 
production due to its renal excretion. (66) Potential participants with UCPCR 
>0.2nmol/mmol had GAD and IA2 autoantibody testing performed. If 
autoantibody testing was negative individuals were tested for monogenic 
diabetes as previously described, and were excluded if found to have 
monogenic diabetes. (96) To avoid inclusion of young onset type 2 diabetes, 
those with UCPCR >0.2nmol/mmol who were islet autoantibody negative were 
excluded if they had a BMI >30kg/m2. 96% of participants were white British. All 
participants provided informed consent and the National Research Ethics 
Service Committee South West approved the study (13/SW/0312).  
Confirmation of C-peptide status 
C-peptide status was confirmed using a standard mixed-meal tolerance test 
(MMTT). This test was either performed at the Exeter National Institute for 
Health Research (NIHR) Clinical Research Facility (CRF), or at home where 
patients were visited by the study nurse. All participants fasted from midnight 
and did not take their morning insulin. Individuals were given a standard MMTT 
(Fortisip Compact, Nutricia, UK) consisting of 160ml containing per 100ml: 
240kcal, 9.6g protein, 9.3g fat and 29.7g carbohydrate. Participants attending 
the CRF had a full multiple time point MMTT, with samples taken at 0, 30, 60, 
90, and 120 minutes post meal. Participants visited at home had an abbreviated 
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single time point MMTT, with a blood sample taken at 90 minutes post meal. 
Serum C-peptide was analysed using a direct electrochemiluminescence 
immunoassay (Roche Diagnostics, Mannheim, Germany). We confirmed C-
peptide group, preserved (>20pmol/l) or low (<10pmol/l) using serum C-peptide 
post MMTT to ensure participants remained in the pre-defined groups. 8 
recruited participants were excluded from further analysis as a result of 
discordant C-peptide on mixed-meal tolerance testing. These participants all 
had high C-peptide in the UNITED study, but serum C-peptide <20pmol/l after 
MMTT.  
Assessment of hypoglycaemia 
Participants completed a modified Clarke’s Hypoglycaemia Questionnaire to 
assess rate and awareness of hypoglycaemia at the time of MMTT. The 
questionnaire is comprised of eight multiple choice questions, with answers 
being scored as 0 (aware) or 1 (reduced awareness). The maximum score is 7 
and a score ≥4 indicates reduced hypoglycaemic awareness. (97) Rates of 
hypoglycaemia were determined by response to questions 5 and 6, they record 
frequency of hypoglycaemic episodes in the last month (defined as blood 
glucose <3.5mmol/l) with and without symptoms during the episode 
respectively, as previously described. (101) Frequency of episodes was taken 
as a monthly average; those answering “1-3 episodes in the last month” were 
averaged to 2; “once a week” to 4 (1x4); “2-3 episodes per week” to 10 (2.5x4); 
“4-5 episodes per week” to 18 (4.5x4), and “almost daily” to 25. 
Assessment of HbA1c and microvascular complications 
HbA1c was measured at the study visit and a historic HbA1c mean calculated 
from a local laboratory records. With informed consent we collected historic 
glycaemic control data from a biochemistry laboratory download of all recorded 
samples over the preceding 12 years in participants from our local area. HbA1c 
was measured at this time using ion exchange chromatography HPLC on the 
TOSOH G8 Analyser (TOSOH Diagnostics, Tokyo, Japan) and standardised to 
IFCC. Historic HbA1c mean was calculated for each participant from all 
available results prior to recruitment (median (IQR) of 18 (12, 26) observations 
over 8 (5, 10) years). 
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For participants from our local area clinical data on microvascular complications 
was obtained from hospital laboratory and retinal screening records. These 
records were not available for participants whose general practice used the 
laboratory & retinal screening service of other regional hospitals. Retinopathy 
status was obtained from participant’s most recent retinal screening record. The 
worst grade of retinopathy identified at the retinal screening visit prior to 
recruitment was recorded. Nephropathy status was defined according to 
whether an individual had ever had clinically defined microalbuminuria, as 
based on their biochemistry records. Microalbuminuria was defined as having 2 
of 3 consecutive albumin-creatinine ratios high (>2.5mg/mmol for men and 
>3.5mg/mmol for women).  
Statistical analysis 
Analysis was carried out using Stata Statistical Software: Release 14 
(StataCorp, Tx, USA). Non-parametric statistical tests were used for analysis if 
on visual examination key continuous outcome variables, were non-normally 
distributed. Differences in clinical parameters were assessed using the Mann 
Whitney U Test. Differences in the severity of retinopathy (characterised as 
none, background, pre-proliferative or proliferative) were compared using a 
Kruskal-Wallis test. Hypoglycaemia rates were considered to follow a Poisson 
distribution. Therefore, results are displayed as rates and incidence rate ratios, 
with confidence intervals also in the Poisson distribution. Statistical significance 
was defined as p<0.05 for all statistical tests. 
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Results 
70 participants with preserved C-peptide and 151 with low C-peptide were 
included in this analysis (characteristics presented in Table 1). Median (IQR) C-
peptide was 114 pmol/l (43, 273) in the preserved C-peptide group, and <3 
pmol/l (<3, <3) in the low C-peptide group. Whilst duration of diabetes was 
similar between the two groups (median 13 years in both groups, p=0.2), the 
preserved C-peptide group were diagnosed at an older age, 15 vs 6 years 
(p<0.0001).  
 
Table 1 – Cohort Characteristics. Values reported as n (%) or median (IQR). 
Characteristics Low C-peptide Preserved C-peptide p value 
No. of participants  151  70  - 
No. Male (%) 86 (57) 29 (41) 0.03 
Age at diagnosis (years) 6.1 (3.0, 12.5) 15.1 (12.2, 22.0) <0.0001 
Age at recruitment (years) 19.9 (14.3, 36.5) 30.9 (20.8, 42.1) 0.0001 
BMI (kg/m²) 23.3 (20.2, 26.5) 25.2 (23.3, 27.3) 0.0006 
BMI standard deviation score 0.8 (0.1, 1.5) 1.0 (0.5, 1.6) 0.2 
Duration of diabetes (years) 13.3 (8.5, 24.5) 12.6 (7.5, 22.0) 0.2 
C-peptide (pmol/l) <3 (<3, <3) 114 (43, 273) <0.0001 
HbA1c (mmol/mol) 67 (58, 76) 69 (62, 81) 0.6 
HbA1c (%) 8.3 (7.5, 9.1) 8.5 (7.8, 9.6) 0.6 
Insulin dose (U/kg in 24 h) 0.81 (0.67, 0.95) 0.68 (0.54, 0.94) 0.01 
No. in hypoglycaemia rate analysis (%) 121 (80) 39 (56) - 
No. in historic HbA1c analysis (%) 86 (57) 67 (96) - 
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Participants with preserved C-peptide had lower rates of hypoglycaemia. 
Partial questionnaire data was available on 160 participants, with complete data 
on 151 (Table 1 and Table 2). The preserved C-peptide group had 21% fewer 
symptomatic episodes per month (IRR 0.79, CI 0.68-0.91, p=0.001), 5.9 vs 7.5 
episodes/month; and 65% fewer asymptomatic episodes per month (IRR 0.35, 
CI 0.25-0.48, p<0.001), 1.0 vs 2.9 episodes/month (Fig. 1 and Fig. 2). There 
was no difference in Clarke score between the two groups (p=0.3), or proportion 
with a reduced hypoglycaemic awareness (score ≥4 out of 7, 16% vs 19% 
p=0.6; Fig. 3). 
 
Table 2 – Hypoglycaemia analysis cohort characteristics. Values reported as n 
(%) or median (IQR). 
Characteristics Low C-peptide Preserved C-peptide p value 
No. of participants 121 39 - 
No. Male (%) 69 (57) 17 (44) 0.1 
Age at diagnosis (years) 5.7 (2.9, 10.8) 15.0 (12.2, 24.0) <0.0001 
Age at recruitment (years) 18.4 (13.5, 34.5) 29.3 (20.4, 43.0) 0.0004 
BMI (kg/m²) 23.3 (19.6, 26.2) 24.5 (22.1, 27.4) 0.02 
BMI standard deviation score 0.9 (0.1, 1.4) 0.8 (0.3, 1.5) 0.8 
Duration of diabetes (years) 12.6 (8.3, 20.8) 12.1 (7.5, 21.4) 0.4 
C-peptide (pmol/l) <3 (<3, <3) 108 (37, 208) <0.0001 
HbA1c (mmol/mol) 67 (57, 75) 68 (59, 80) 0.4 
HbA1c (%) 8.3 (7.4, 9.0) 8.4 (7.5, 9.5) 0.4 
Insulin dose in 24 h (U/kg) 0.80 (0.67, 0.95) 0.71 (0.55, 0.94) 0.09 
No. in hypoglycaemia awareness analysis 113  38 - 
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Fig. 1 – Total monthly rate of hypoglycaemia by C-peptide group. Rates of 
aware (blue) and unaware (green) episodes with blood glucose <3.5mmol/l per 
month; derived from Clarke’s hypoglycaemia questionnaire questions 5 and 6 
respectively. ****p<0.0001, for low (n=118) vs preserved (n=39) C-peptide. Error 
bars represent 95% CI. 
 
Fig. 2 – Hypoglycaemia rates by C-peptide group. Number of hypoglycaemic 
(blood glucose <3.5mmol/l) episodes per month stratified by aware and 
unaware episodes. Rates derived from Clarkes questions 5 and 6. Low C-
peptide group in blue (aware n=120, unaware n=119) and preserved C-peptide 
group in orange (n=39). ***p≤0.001 for low vs preserved C-peptide. Error bars 
represent 95% CI. 
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Fig. 3 – Reduced hypoglycaemic awareness by C-peptide group. Proportion of 
the low (blue, n=113) or preserved (orange, n=38) C-peptide group with 
reduced hypoglycaemic awareness, defined as a Clarke score ≥4/7. 
Hypoglycaemic awareness was similar in both groups, p=0.6. 
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Both the study visit HbA1c and historic HbA1c means were similar in both 
groups. 
Participants in the preserved group had a marginal trend towards higher study 
visit HbA1c, 69 vs 67mmol/mol (8.5% vs 8.3%), p=0.06 (Fig. 4 and Fig. 5). 
Historic HbA1c mean was calculated in 153 participants (Table 1). The historic 
HbA1c mean was also similar in both groups, 71 vs 68mmol/mol (8.6% vs 
8.4%) in those with high and low C-peptide respectively, p=0.4 (Fig. 6). 
 
 
 
 
Fig. 4 – Boxplot of study visit HbA1c by C-peptide group. Study visit HbA1c was 
similar in the low (n=148) and preserved (n=70) C-peptide groups p=0.06. 
Outliers are shown in Fig. 5. 
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Fig. 5 – Boxplot of study visit HbA1c by C-peptide group. Study visit HbA1c was 
similar in the low (n=148) and preserved (n=70) C-peptide groups p=0.06. 
Including outliers. 
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Fig. 6 - Historic HbA1c mean analysis (a) Boxplot showing similar historic 
HbA1c mean in low (n=86) vs preserved (n=67) C-peptide group, p=0.4. (b) 
Scatter graph of study visit HbA1c and historic HbA1c mean (n=153). 
Spearman’s rho = 0.72, p<0.0001. Low C-peptide group (n=86) shown in blue 
and preserved C-peptide group (n=67) in orange. (c) Boxplot showing similar 
study visit HbA1c (n=153) vs historic HbA1c mean (n=153), p=0.1. 
(a) 
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(c) 
 
Insulin dose was substantially lower in those with preserved C-peptide 
production.  
Participants with preserved C-peptide received a total daily dose of 0.68 
units/kg (0.54, 0.94), whereas those with low C-peptide received 0.81 units/kg 
(0.67, 0.95), for comparison p=0.01 (Fig. 7 and Fig. 8).  
 
Fig. 7 – Boxplot of daily insulin dose by C-peptide group. Insulin dose was 
lower in the preserved C-peptide group (n=70) vs the low (n=151) group, 
p=0.01. Outliers are shown in Fig. 8. 
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Fig. 8 – Boxplot of daily insulin dose by C-peptide group. Insulin dose was 
lower in the preserved C-peptide group (n=70) vs the low (n=151) group, 
p=0.01. Including outliers. 
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Preservation of endogenous insulin secretion was not associated with 
differences in retinopathy or microalbuminuria. 
Retinopathy results were available on 130 participants (Table 3). Presence of 
retinopathy in the preserved C-peptide group was similar to the low group, 66% 
vs 74%, p=0.3 (Fig. 9). There was no difference in grades of retinopathy 
between the two groups (p=0.5).  
 
Table 3 - Complication analysis cohort characteristics. Values reported as n (%) 
or median (IQR). 
 
Characteristics Low C-peptide Preserved C-peptide p value 
No. of participants (%) 81 59 - 
No. Male (%) 46 (57) 23 (39) 0.04 
Age at diagnosis (years) 10.9 (5.2 15.2) 17.0 (12.5, 23.8) <0.0001 
Age at recruitment (years) 34.4 (23.2, 47.9) 34.1 (26.1, 43.6) 0.8 
BMI (kg/m²) 24.5 (22.5, 27.2) 25.5 (22.5, 27.3) 0.6 
BMI standard deviation score 1.0 (0.4, 1.5) 1.0 (0.3, 1.5) 0.9 
Duration of diabetes (years) 21.3 (12.4, 37.8) 14.1 (7.8, 23.2) 0.001 
C-peptide (pmol/l) <3 (<3, 4) 135 (57, 314) <0.0001 
HbA1c (mmol/mol) 66 (58, 78) 69 (63, 81) 0.08 
HbA1c (%) 8.2 (7.5, 9.3) 8.5 (7.9, 9.6) 0.08 
Insulin dose in 24 h (U/kg) 0.75 (0.59, 0.88) 0.67 (0.54, 0.92) 0.2 
No. in retinopathy analysis 74  56 - 
No. in microalbuminuria analysis 69 51 - 
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Fig. 9 – Rates of retinopathy and microalbuminuria by C-peptide group. 
Proportion of C-peptide group with retinopathy in blue; background in dark blue, 
pre-proliferative in medium blue, proliferative in light blue. Proportion with 
retinopathy was similar in the low (n=55/74) vs preserved C-peptide group 
(n=37/56), p=0.3. Proportion of C-peptide group with microalbuminuria (green); 
similar in low (n=16/69) and preserved (n=10/51) C-peptide groups, p=0.6.  
 
 
 
The prevalence of microalbuminuria was also similar in participants with high 
and low C-peptide. Records were available on 120 participants (Table 3). In 
these participants 20% and 23% of those with high and low C-peptide met study 
criteria for microalbuminuria, p=0.6 (Fig. 9).  
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Discussion 
Our study showed that low levels of preserved C-peptide production in long 
duration type 1 diabetes in UK clinical practice were associated with reduced 
hypoglycaemia without improvement in HbA1c. Rates of both symptomatic and 
asymptomatic hypoglycaemia were reduced in the preserved C-peptide group, 
with similar hypoglycaemic awareness and without differences in either single 
measure or historic HbA1c mean. However, those with preserved C-peptide 
were treated with a lower exogenous insulin dose. Consistent with a lack of 
difference in HbA1c, levels of retinopathy and microalbuminuria were not 
different when examined in a subset of our study population. 
These findings mirror the conventionally treated arm of the DCCT. This 
suggests a lack of intensive treatment in UK practice and highlights the 
challenges in achieving tight control outside the closely monitored clinical trial 
setting. The DCCT showed that where intensive diabetes treatment is given, 
higher levels of C-peptide are associated with markedly lower hypoglycaemia, 
HbA1c and microvascular complications even with low levels of secretion below 
200pmol/l. However, benefits were much less marked where conventional 
therapy was given. (6,54,55) While this may be partly explained by more rapid 
loss of endogenous insulin secretion in non-intensively treated participants (55), 
this may also relate to reductions in hypoglycaemia risk associated with 
preserved C-peptide allowing intensification of treatment to a tighter level of 
glycaemic control. The limitation of achieving optimal glycaemic control with 
intensive treatment in type 1 diabetes is usually hypoglycaemia, which prevents 
up-titration of insulin doses. The reduced glucose variability and better 
hypoglycaemia counter regulation associated with preservation of endogenous 
insulin secretion (79,101,108,109) means that with intensive treatment a person 
with retained endogenous insulin secretion can obtain a lower HbA1c at an 
acceptable level of hypoglycaemia than would be possible where endogenous 
insulin is absent.  
Our findings are consistent with previous research on the clinical impact of C-
peptide. Hope et al. observed an approximate doubling in self-reported 
hypoglycaemia in those with type 1 diabetes with C-peptide <200pmol/l 
compared to >200pmol/l. This study focussed on patients diagnosed older with 
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group durations 25 vs 10 years respectively. (101) Kuhtreiber et al. also used 
the Clarke Score to assess hypoglycaemia. They categorised individuals as 
having mild, moderate or severe hypoglycaemia, showing that more severe 
hypoglycaemia was associated with lower levels of C-peptide. In addition, they 
found that higher C-peptide was associated with better glycaemic control and 
fewer complications. Their study had the benefit of a larger sample size and 
was thus better powered to assess a difference in complication rates. (105) Our 
data are also aligned with studies of islet cell transplant recipients. In this setting 
even minimal graft function, measured by C-peptide or beta score, correlates 
with reduced hypoglycaemia risk and improved glycaemic variability. (77–
79,81,106) Vantyghem et al. showed that in islet cell transplant recipients partial 
beta cell function reduced rates of hypoglycaemia however improvements in 
glycaemic control and variability required significantly better graft function. (81) 
Combined these findings point toward endogenous insulin control playing a key 
role in preventing hypoglycaemia; perhaps directly by stopping secretion when 
blood glucose levels fall or indirectly through counter-regulatory hormones such 
as glucagon.   
Strengths of our study include that we were able to utilise a highly sensitive C-
peptide assay, allowing for identification and classification of C-peptide status at 
historically undetectable levels. We also robustly excluded individuals with both 
Type 2 and monogenic diabetes, ensuring that those with a high C-peptide truly 
had type 1 diabetes. Additionally, our recruitment process allowed the disease 
duration of both groups to be the same, removing a potential key confounder 
from this analysis. Our cohort were not part of a clinical intervention trial and 
received routine clinical care, making them reflective of current type 1 diabetes 
management in the UK, both strengthening our findings and making them 
relevant to routine care in the UK.  
Our study was limited by self-reported hypoglycaemia and region restricted 
complication data reducing the power to assess a difference in complications. 
We used a validated hypoglycaemia questionnaire, however, this relied on 
participants both correctly identifying and recording hypoglycaemic episodes. It 
would be valuable to carry out continuous glucose monitoring on a cohort of 
similar patients, looking to remove participant bias and potentially validate our 
findings. In addition, we were only able to obtain data on complications on 
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participants based in the Exeter area, due to availability of medical records. This 
reduced our power to identify differing rates of retinopathy and 
microalbuminuria, so we could not rule out smaller differences that still may be 
clinically relevant. The sample size for our complication analysis provided 80% 
power (alpha 0.05), to detect a difference in proportions of 30% for both 
retinopathy and microalbuminuria, therefore meaningful differences in 
complications may not be detected with our limited sample size. A further 
limiting factor to this analysis was the selection criteria for our study, which 
excluded people with renal impairment, as C-peptide is renally excreted and 
therefore less reflective of endogenous beta cell function in those with impaired 
renal function. (66) 
Notwithstanding these limitations, our study suggests a need to intensify 
treatment in those with persistent C-peptide. The DCCT demonstrated that the 
benefits of persistent C-peptide production could only be fully utilized when 
individuals received intensive therapy. Our study focused on those receiving 
routine clinical care and did not show the improvement of HbA1c associated 
with persistent C-peptide in the DCCT, with the benefit of maintained 
endogenous insulin secretion limited to lower insulin dose and less 
hypoglycaemia. A lack of impact on microvascular complications is therefore 
unsurprising considering >10 years of HbA1c records showed similar glycaemic 
control in both groups. We consider the most likely explanation for this finding to 
be a lack of intensive treatment, showing that factors other than hypoglycaemia 
limit achievement of HbA1c targets. Clinicians do not routinely test C-peptide 
and there are currently no guidelines to treat those with persistent C-peptide, 
who are protected from hypoglycaemia, more intensively. Therefore these 
patients may be considered to have acceptable glycaemic control in practice, 
when they would be able to achieve tighter glycaemia control and reduce risk of 
long term complications with more intensive treatment, without unacceptable 
hypoglycaemia. Targeted intensification of treatment in those with preserved C-
peptide would therefore be a potential clinical strategy to improve control and an 
important area for future study. 
Our study highlights the association of persistent high C-peptide with reduced 
hypoglycaemia. Additionally, it demonstrates that higher C-peptide does not 
always robustly associate with improved glycaemic control and reduced 
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complications rates. This may be a consequence of all patients being treated to 
the same glycaemic targets, irrespective of C-peptide production. The apparent 
under-treatment of those with preserved C-peptide production makes our 
assessment of any complication benefit difficult.  
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Abstract 
Aims 
Insulin induced hypoglycaemia remains a barrier to intensive diabetes 
treatment. There are currently no biomarkers used to assess hypoglycaemic 
risk. While glucagon protects from hypoglycaemia in health, there is significant 
glucagon dysregulation in type 1 diabetes. This study aims to assess the 
relationship between mixed-meal tolerance test (MMTT) stimulated glucagon 
and hypoglycaemia in long duration type 1 diabetes.  
Methods 
We assessed glucagon at 90 minutes following a MMTT in 133 participants with 
long duration (>5 years) type 1 diabetes. We investigated the relationship 
between stimulated glucagon and self-reported hypoglycaemia using Clarke’s 
hypoglycaemia questionnaire in 72 participants.  
Results 
Median (IQR) glucagon at 90 minutes was 2.1pmol/l (<1.5, 3.9). Median (IQR) 
disease duration was 17.3 years (11.4, 30.2). In the majority of participants 
glucagon secretion increased in response to the MMTT (53%). Higher 90-
minute glucagon was associated with a markedly lower reported rate of 
hypoglycaemia. Glucagon explained 11% of variation in hypoglycaemia rate 
and for a 1pmol/l increase total monthly hypoglycaemia rate was reduced by 
23% (pseudo R²=0.11, IRR 0.77, CI 0.72-0.81, p<0.0001). When used in 
combination stimulated glucagon, C-peptide and HbA1c explained 24% of 
variation in overall hypoglycaemia rate. 
Conclusion 
In this study MMTT stimulated glucagon was a significant predictor of 
hypoglycaemia rate, this was independent of HbA1c, C-peptide and disease 
duration. This highlights the potential for glucagon to be used as a biomarker of 
hypoglycaemia risk and its utility in individualising treatment strategy. 
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Introduction 
Hypoglycaemia is a common, dangerous complication of insulin treatment in 
type 1 diabetes. 2-4% of deaths in people with type 1 diabetes are attributed to 
hypoglycaemia. (29) This potentially life threatening complication poses the 
largest barrier to achieving tight glycaemic control. (25,100) Management 
hinges on balancing hypoglycaemia risk and maintaining good glycaemic 
control so as to prevent the development of microvascular complications. As 
such, it is important to recognise individuals at high risk of hypoglycaemia. The 
Diabetes Control and Complications Trial (DCCT) showed the incidence of 
severe hypoglycaemia was three times higher in the intensively treated arm 
when compared to the conventionally treated. (50,74) Strict glycaemic control is 
a risk factor for hypoglycaemia, but the DCCT showed that HbA1c only explains 
6-12% of variation in severe hypoglycaemia rate. (110,111) Other risk factors 
include increasing disease duration, increasing age and reduced hypoglycaemic 
awareness. (25,100) Reduction of hypoglycaemia risk relies upon patient 
education, more frequent monitoring of blood glucose with subsequent 
adjustment of insulin dose, and less intensive treatment with individualised 
blood glucose and HbA1c targets. Identification of individuals at high 
hypoglycaemic risk is key in improving type 1 diabetes management. (100) 
However, currently there are no biomarkers to predict those most at risk of 
hypoglycaemia.  
There is very little data on the relationship between glucagon levels and 
hypoglycaemia in type 1 diabetes due to historic difficulties with glucagon 
assays. (95) Ordinarily glucose homeostasis is maintained by the opposing 
effects of alpha and beta cells, secreting glucagon and insulin respectively. 
Glucagon is supressed in response to increasing blood glucose and secreted in 
response to falling blood glucose so as to prevent hypoglycaemia. However, in 
type 1 diabetes there is significant glucagon dysregulation. (7,29)  
Hypoglycaemic clamp studies have shown inadequate secretion in response to 
hypoglycaemia. (88) While other studies have shown inappropriate glucagon 
secretion in response to a meal. (89–92) In addition, glucagon response 
appears to become increasingly dysregulated with increasing disease duration 
and declining beta cell function. (88,89,112,113) However, there is no existing 
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literature robustly assessing meal stimulated glucagon in a cohort with long 
duration type 1 diabetes, a group at high risk of hypoglycaemia where glucagon 
regulation is key.  
Our aim is to assess the relationship between glucagon secretion measured 
during a mixed-meal tolerance test (MMTT), and hypoglycaemia in long-
duration type 1 diabetes. We will be using MMTT data from the TIGI (Type 1 
diabetes Immunology, Genetics and endogenous Insulin production) study. The 
primary outcome of the TIGI study was a comparison of immune phenotype in 
people in high and low C-peptide defined groups. Hypoglycaemia questionnaire 
data was collected as a clinically relevant secondary outcome and whilst 
immune analyses are ongoing we are able to report hypoglycaemia outcomes.  
 
  
80 
 
Methods 
Study participants  
The TIGI study is a cross-sectional, observational case-control study in the UK. 
TIGI participants were recruited from the population study UNITED (Using 
pharmacogeNetics to Improve Treatment in Early onset Diabetes). In UNITED 
all participants had clinically diagnosed type 1 diabetes before the age of 30 
and were under the age of 50 at the time of study recruitment. The UNITED 
study recorded a urine C-peptide-creatinine ratio (UCPCR) on all participants. 
(53) 
Potential TIGI participants were then selected on the basis of having diabetes 
for >5 years and being in the top or bottom quintile of UCPCR for their disease 
duration. All TIGI participants were on insulin treatment from diagnosis and 
living in the South West of England. Young onset type 2 diabetes and 
monogenic diabetes were robustly excluded, as previously described. (2,53)  
All participants provided informed consent and the study was approved by the 
National Research Ethics Service Committee South West (13/SW/0312). 
Study visit 
A sub-group of the TIGI cohort were visited by a study nurse at home. This 
analysis excludes those visited at home due to concerns regarding the stability 
of glucagon in transit. All other participants visited the Exeter National Institute 
for Health Research (NIHR) Clinical Research Facility (CRF) for a single study 
visit.  
All participants attending the CRF completed a multiple time point MMTT, 
having fasted from midnight and not taken their morning insulin. Each 
participant was given 160ml of Fortisip Compact (Nutricia, UK), containing 
240kcal, 9.6g protein, 9.3g fat and 29.7g carbohydrate per 100ml. Blood 
samples for C-peptide and glucose were taken at 0, 30, 60, 90 and 120 
minutes. Blood samples were spun and stored at -80⁰C prior to analysis. 
Glucagon was measured at 0 and 90 minutes. Serum C-peptide was analysed 
using a direct electrochemiluminescence immunoassay (Roche Diagnostics, 
Mannheim, Germany). Glucagon was analysed using the Mercodia Glucagon 
ELISA (Mercodia, Uppsala, Sweden) on the Dynex D2 ELISA (Dynex, Lincoln, 
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UK) robot platform, with a lower limit of detection on 1.5pmol/l. HbA1c was also 
measured, using ion exchange chromatography HPLC on the TOSOH G8 
Analyser (TOSOH Diagnostics, Tokyo, Japan) and standardised to IFCC.  
Hypoglycaemia analysis 
Participants completed Clarke’s Hypoglycaemia questionnaire at the study visit. 
This was a secondary outcome of the TIGI study and was added to the study 
protocol after some participants had been recruited. As such, questionnaires 
are only available on a subset of participants. Clarke’s Hypoglycaemia 
questionnaire is a validated hypoglycaemia questionnaire used to assess both 
hypoglycaemic unawareness and rate of hypoglycaemia. (97,100,101,103) 
There is a total of 8 multiple choice questions, where answers are scored as 
zero for aware or one for reduced awareness, with a maximum score of 7. An 
individual with a score ≥4 is defined as having reduced hypoglycaemic 
awareness. Monthly rates of symptomatic and asymptomatic hypoglycaemia 
can be calculated using answers 5 and 6 respectively. Hypoglycaemia is 
defined as a blood glucose <3.5mmol/l. Participants are asked how many times 
in the last month their blood glucose has been <3.5mmol/l both with (question 
5) and without (question 6) symptoms. Monthly frequency can then be 
estimated from the participant’s answer, with “Never” being recorded as 0; “1-3 
times” as 2; “1 time per week” as 4 (1x4); “2-3 times per week” as 10 (2.5x4); 
“4-5 times per week” as 18 (4.5x4); and “almost daily” estimated at 25. For this 
analysis we combined the symptomatic and asymptomatic rates to give a total 
monthly rate of hypoglycaemia. (97,101)  
Statistical analysis 
Statistical analyses were carried out using Stata Statistical Software: Release 
14 (StataCorp, Tx, USA). Statistical significance was set at p<0.05 for all 
statistical tests. Glucagon at 90 minutes post-meal was non-normally distributed 
both visually and using Shapiro Wilk testing (p<0.00001).  Therefore, non-
parametric tests were used throughout the analysis. Clinical variables were 
tested using Mann Whitney-U and Spearman’s Rank tests. Hypoglycaemia 
rates were considered to follow a Poisson distribution; thus, results are 
presented as rates and incidence rate ratios (IRR) with confidence intervals also 
reported using a Poisson distribution.  
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Results 
The characteristics of the 133 participants contributing to this analysis can be 
seen in Table 1. 94% of participants were white British. Glucagon at 90 minutes 
ranged from the lower limit of the assay (1.5 pmol/l) to 9.6pmol/l; with a median 
(IQR) of 2.1pmol/l (<1.5, 3.9). Median (IQR) disease duration was 17.3 years 
(11.4, 30.2).  
Table 1 - Cohort characteristics. Values reported as n (%) or median (IQR). 
 n (%) or median (IQR) 
No. of participants 133 
No. Male (%) 59 (44%) 
Age at diagnosis (years) 13.5 (8.25, 19.75) 
Age at recruitment (years) 34.14  (24.08, 45.09) 
Duration of diabetes (years) 17.33 (11.44, 30.19) 
BMI standard deviation score 0.96 (0.37, 1.52) 
HbA1c (mmol/mol) 68 (59, 80) 
Insulin dose (U/kg in 24 h) 0.71 (0.55, 0.85) 
Glucagon at 90 mins (mmol/l) 2.1 (<1.5, 3.9) 
C-peptide at 90 mins (pmol/l) 5 (<3, 94) 
Glucose increment (mmol/l) 10 (8.7, 11.5) 
 
Post-meal glucagon increased in the majority of participants.  
Incremental glucagon from fasting to 90 minutes could be calculated in 122 
participants. Median (IQR) glucagon increment was 0.3 pmol/l (0, 1.8). In the 
majority (65/122) glucagon secretion increased. In 18/122 participant’s 
glucagon secretion decreased and in 39/122 participants glucagon secretion 
remained the same. All participants whose glucagon secretion remained the 
same had glucagon at the lower limit of the assay at both time points.  
Higher 90-minute glucagon was associated with a reduced insulin dose, 
longer disease duration and older age at both diagnosis and recruitment, 
but not with C-peptide. 
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Analysis of glucagon at 90 minutes with key clinical characteristics was carried 
out in all 133 participants, with the exception of HbA1c in which one participant 
did not have HbA1c recorded.  
Higher 90-minute glucagon was associated with older age at diabetes 
diagnosis, Spearman’s rho = 0.18, p=0.04 (Fig. 1a); older age at recruitment to 
TIGI, Spearman’s rho = 0.40, p<0.0001 (Fig. 1b); and longer disease duration, 
Spearman’s rho = 0.31, p=0.0002 (Fig. 1c). 
Higher glucagon at 90 minutes correlated with a lower daily insulin dose, 
Spearman’s rho = -0.21, p=0.02 (Fig. 1d). There was no relationship between 
90-minute glucagon and 90-minute C-peptide, p=0.2.  
Fig. 1 – Analysis of glucagon at 90 minutes (a) Scatter graph of age at 
diagnosis and 90-minute glucagon (n=133). Spearman’s rho = 0.18, p=0.04.  
(b) Scatter graph of age at recruitment and 90-minute glucagon (n=133). 
Spearman’s rho = 0.40, p<0.0001. (c) Scatter graph of disease duration and 90-
minute glucagon (n=133). Spearman’s rho = 0.31, p=0.0002. (d) Scatter graph 
of daily insulin dose and 90-minute glucagon (n=133). Spearman’s rho = -0.21, 
p=0.02. 
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Higher 90-minute glucagon was associated with a markedly lower 
reported rate of hypoglycaemia.  
Hypoglycaemia questionnaires were completed by 72 participants. Glucagon at 
90 minutes was not associated with overall Clarke score (p=0.09) or 
hypoglycaemic unawareness (p=0.5).  
Higher glucagon at 90 minutes was associated with a lower monthly rate of 
symptomatic, asymptomatic and total monthly rate of hypoglycaemia. For a 
1pmol/l increase in stimulated glucagon, symptomatic hypoglycaemia rate 
decreased by 22% (IRR 0.78, CI 0.73-0.83, p<0.0001), asymptomatic by 33% 
(IRR 0.67, CI 0.56-0.80, p<0.0001) and total monthly hypoglycaemia rate by 
23% (IRR 0.77, CI 0.72-0.81, p<0.0001) (Fig. 2). 
 
Fig. 2 - Scatter graph showing total monthly hypoglycaemia rate and glucagon 
at 90 minutes (n=72). Glucagon 90-minutes post-meal explains 11% of variation 
in total hypoglycaemia rate and a 1pmol/l increase reduces rate by 23% (IRR 
0.77, CI 0.72-0.81, p<0.0001, pseudo R²=0.11). 
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Glucagon at 90 minutes in combination with C-peptide at 90 minutes and 
HbA1c can be used to explain 24% of variation in total hypoglycaemia 
rate. 
Alone stimulated glucagon explains 11% of variation in total hypoglycaemia rate 
and a 1pmol/l increase reduces rate by 23% (IRR 0.77, CI 0.72-0.81, p<0.0001, 
pseudo R²=0.11). 90-minute C-peptide when used alone explains 4% of 
variation in total rate of hypoglycaemia and a 1pmol/l increase reduces 
hypoglycaemia rate by 0.2% (IRR 0.998, CI 0.997-0.999, p<0.0001, pseudo 
R²=0.04). HbA1c when used alone explains 3% of variation in hypoglycaemia 
rate and a 1mmol/mol increase reduces the risk of hypoglycaemia by 1% (IRR 
0.99, CI 0.98-0.99, p<0.0001, pseudo R²=0.03). When used in combination 
stimulated glucagon, C-peptide and HbA1c explain 24% of variation in total 
hypoglycaemia rate (Table 2). 
Both disease duration and age at TIGI were only significant when used in the 
model alongside glucagon at 90 minutes and both then lost significance when 
used in conjunction with HbA1c. In contrast, age at diagnosis was significant 
when used in univariate analysis, however, lost significant when used in 
conjunction with glucagon and C-peptide. Similarly, glucose at 90 minutes was 
significant alone, however, when used in the model alongside glucagon at 90 
minutes it was no longer significant. 
 
Table 2 - Poisson regression analysis of total monthly hypoglycaemia rate 
(n=71). Pseudo R²=0.24 
 
  
Variable IRR Std. Error z p-value 95% CI 
Glucagon at 90 mins (pmol/l) 0.735 0.0335 -9.20 <0.0001 -0.3739 -0.2425 
C-peptide at 90 mins (pmol/l) 0.998 0.0004 -6.41 <0.0001 -0.0032 -0.0017 
HbA1c (mmol/mol) 0.979 0.0031 -6.87 <0.0001 -0.0278 -0.0154 
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Discussion 
In people with longstanding type 1 diabetes, higher glucagon at 90 minutes was 
associated with a substantially lower rate of hypoglycaemia, this effect was 
independent of glucose at 90 minutes, disease duration, C-peptide and HbA1c. 
This suggests its potential as a tool for assessment of hypoglycaemia risk. In 
53% (65/122) of participants glucagon inappropriately increased in response to 
a MMTT. Our findings support research demonstrating glucagon dysregulation 
in type 1 diabetes. Furthermore, they suggest that despite dysregulation, 
glucagon continues to play a key role in prevention of hypoglycaemia; with 
those that exhibit a higher glucagon 90 minutes post-meal having markedly 
lower rates of hypoglycaemia. Interestingly, glucagon was the biomarker that 
explained the most variance in rate of hypoglycaemia when used alone (11%). 
It is important to take into account the scales on which these biomarkers are 
measured when considering the impact of a single unit increase. Whilst 
glucagon was the biomarker with that provided the largest reduction in 
hypoglycaemia risk for a 1pmol/l increase (23%) (cohort range <1.5, 9.6), it was 
also the biomarker with the smallest range. In a multivariate Poisson regression 
model, C-peptide, HbA1c and glucagon were additive, with glucagon having the 
largest contribution to overall variation in hypoglycaemia rate. Up until now 
there has been very little research into the relationship between stimulated 
glucagon and hypoglycaemia. To our knowledge this is the first study to 
consider this relationship in long-duration type 1 diabetes, a cohort at high 
hypoglycaemic risk. Our study highlights the importance of future research into 
stimulated glucagon and its relationship with hypoglycaemia in type 1 diabetes.  
 
Our study has both strengths and limitations. A strength of our study is that we 
assessed post-meal glucagon in a cohort with long-duration type 1 diabetes. 
Our cohort had a wide range of disease durations which allowed us to assess 
the effect of duration on glucagon dysregulation robustly. In addition, the study 
design meant that we recruited participants with both high and low levels of C-
peptide for their duration. This enabled us to assess the effect of duration and 
C-peptide on glucagon separately. Furthermore, we were able to utilise a 
robust, well validated glucagon assay, this has previously been a barrier to 
glucagon studies. Another strength is that we assessed the association of post-
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meal glucagon with hypoglycaemia. Most research has focused on intensive 
studies during hypoglycaemia, and it is not immediately intuitive to assess 
glucagon post meal when it would be expected to decrease. This is likely to be 
the reason why the association between MMTT stimulated glucagon and 
hypoglycaemia has not been recognised before, making this an important 
finding. Avoidance of hypoglycaemia is a key component of diabetes 
management, particularly for those with longer disease duration. As such 
understanding the role of glucagon in type 1 diabetes is important and has the 
potential to direct future management.  
 
A limitation of the study was that monthly hypoglycaemia rate was not recorded 
in all participants. This was due to questionnaires not being collected at the 
beginning of the study period. Analysis comparing those with and without 
hypoglycaemia questionnaires showed the groups to be broadly similar, 
however, those not included in the hypoglycaemia analysis had higher HbA1c 
and C-peptide but lower glucagon (Table 3). A further limitation was the use of 
hypoglycaemia questionnaires to calculate hypoglycaemia rates. 
Questionnaires rely on participants to correctly recognise and recall 
hypoglycaemic events and the very nature of hypoglycaemia can make this 
difficult. It has been reported that individuals with type 1 diabetes self-report 
having almost half as many hypoglycaemic events as their closest cohabitant 
recalls. (114) Participants may not always be aware of hypoglycaemic episodes. 
This may be due to reduced hypoglycaemic awareness, which is a particular 
problem in long duration cohorts. Alternatively, this could be due to nocturnal 
hypoglycaemia, with almost 50% of hypoglycaemic events occurring during 
sleep. (25) As such, the questionnaire is likely to have vastly underestimated 
the true rate of hypoglycaemia. We additionally have considerable noise around 
the hypoglycaemia assessment, suggesting that the combined approach of 
glucagon, C-peptide and HbA1c may even be a stronger predictor of 
hypoglycaemia variation if hypoglycaemia was more precisely measured. 
Nonetheless, this makes our finding more remarkable as despite a noisy 
measure of hypoglycaemia its association with post-meal glucagon was striking.  
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Table 3 - Comparison of those include in the hypoglycaemia analysis to the 
remaining cohort. Values reported as n (%) or median (IQR). 
 Hypoglycaemia analysis Not in hypoglycaemia analysis p-value 
No. of participants 72 61 
 
No. Male (%) 31 (43%) 28 (46%) 0.7 
Age at diagnosis (years) 13.4 (7.83, 21.33) 13.9 (9.75, 19.33) 0.9 
Age at recruitment (years) 35.1 (23.46, 48.07) 31.3 (24.46, 41.18) 0.1 
Duration of diabetes (years) 19.3 (12.59, 35.42) 15.3 (8.52, 27.52) 0.06 
BMI standard deviation score 1.06 (0.51, 1.51) 0.86 (0.32, 1.54) 0.4 
HbA1c (mmol/mol) 66 (56, 74) 71 (61, 82) 0.03 
Insulin dose (U/kg in 24 h) 0.71 (0.55, 0.80) 0.73 (0.55, 0.98) 0.2 
Glucagon at 90 mins (mmol/l) 3.0 (<1.5, 4.3) 1.5 (<1.5, 2.4) 0.0002 
C-peptide at 90 mins (pmol/l) 
<3 (<3, 58.5) 20 (5, 149) <0.0001 
Glucose increment (mmol/l) 10.15 (8.9, 12.2) 9.7 (8.45, 11.20) 0.3 
Glucose at 90 mins (mmol/l) 21.2 (18.3, 24.5) 21.5 (18.4, 24.5) 0.9694 
 
Glucagon is well established as an important counter-regulatory hormone 
protecting from hypoglycaemia in healthy people and people with diabetes. (7) 
Glucagon dysregulation is known, in intensive physiology studies of type 1 
diabetes, to associate with less protection from hypoglycaemia. (93,94) It has 
been suggested that in healthy people endogenous insulin production regulates 
glucagon release, with falling levels stimulating glucagon secretion. In type 1 
diabetes this regulatory effect is lost with declining beta cell function. Glucagon 
secretion becomes driven by a rise in blood glucose, resulting in inappropriate 
glucagon production post-meal and inadequate production in hypoglycaemia. 
(7) Simple measures of glucagon during stimulation tests have been less well 
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studied, presumably because glucagon is thought not to be relevant at this time. 
It has been established that glucagon inappropriately rises following a meal, 
with Sherr et al reporting that in individuals with type 1 diabetes glucagon levels 
post-MMTT were 1.5 times greater than when measured fasting. (90) In 
addition, Brown et al. followed 23 children for 1 year following diagnosis and 
carried out a MMTT every 3 months. They showed over the 12 months that as 
disease duration increased, stimulated C-peptide gradually declined by 45% 
and post-meal glucagon progressively increased by 37%. (89) However, very 
little is known about post-meal glucagon beyond its relationship with duration. 
To our knowledge this is the first study to focus on stimulated glucagon and its 
associations in long duration type 1 diabetes. Whilst we are unable to fully 
explain the relationship between higher post-meal glucagon and lower rate of 
hypoglycaemia it is nevertheless a key finding. Importantly, stimulated glucagon 
explained variation in hypoglycaemia rate better than any other variable, 
including duration. This highlights its potential utility as a biomarker of 
hypoglycaemia risk. 
 
Interestingly, we did not see a relationship between C-peptide and 90-minute 
glucagon. This was also the case for Sherr et al. In contrast, Brown et al. 
demonstrated decreasing C-peptide was associated with an increasingly high 
glucagon response post-meal. (89,90) This may be due to having populations 
with vastly different disease durations. Alternatively it may be that a single 
measure was unable to detect the relationship between C-peptide and glucagon 
within an individual. (90) Recently Zenz et al. used hypoglycaemic clamps to 
compare individuals with detectable and un-detectable C-peptide. They showed 
that while both groups secreted glucagon in response to hypoglycaemia, levels 
were markedly higher in those with detectable C-peptide. Notably, median 
disease duration was markedly different between the C-peptide positive and 
negative participants (2.5 vs 23.9 years, p<0.001). (88) It is possible that the 
observed difference in glucagon response was due to differing duration rather 
than C-peptide level.  
 
Glucagon at 90 minutes has the potential to be used as a biomarker of 
hypoglycaemia risk. Identifying individuals at risk of hypoglycaemia is a vital 
component of type 1 diabetes management. Intensive treatment, to minimise 
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development of microvascular complications, comes at the cost of increased 
risk of life-threatening hypoglycaemia. Currently there are no biomarkers for 
hypoglycaemia risk outside of HbA1c and the theoretical association of 
hypoglycaemia with C-peptide. Clinicians must use disease duration, 
hypoglycaemic awareness and history of hypoglycaemia to determine risk and 
decide how intensively to treat an individual. Accurately assessing and 
monitoring hypoglycaemia risk using a combined biomarker and clinical features 
approach would be beneficial in determining individualised treatment strategies. 
Our study shows that the combination of post-meal glucagon, C-peptide and 
HbA1c explains 24% of variation in hypoglycaemia rate. As a combined 
biomarker of hypoglycaemia risk, this would provide an invaluable tool for risk 
assessment. Clinicians could provide those with a lower risk with intensive 
treatment to prevent microvascular complications. In contrast those at higher 
risk might require more careful glucose monitoring and possibly a higher target 
HbA1c and blood glucose, to avoid hypoglycaemia. This would also highlight 
individuals who would benefit from hypoglycaemia education and more frequent 
blood glucose monitoring. Future research should further investigate the 
association between higher post-meal glucagon and reduced risk of 
hypoglycaemia, using continuous glucose monitoring to assess frequency of 
hypoglycaemia. In addition, other potential biomarkers, such as C-peptide, 
should be assessed for utility in determining risk of hypoglycaemia; with the 
view to provide a combined biomarker of hypoglycaemia risk to be used by 
clinicians when deciding individualised treatment strategies. It would also be 
useful to investigate the importance of glucagon being measured at 90 minutes 
following a standardised MMTT, when used as a potential biomarker of 
hypoglycaemic risk. Exploring the utility of both fasting and random glucagon 
measurements, alongside measurement after a non-standardised meal, would 
be beneficial when determining the most informative and efficient way to 
measure glucagon in clinical practice. In addition, our study highlighted the 
significance of glucagon dysregulation in type 1 diabetes and its importance in 
avoiding hypoglycaemia. Future work should further evaluate the inclusion of 
glucagon in combination with insulin in closed-loop systems. (115,116)  
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In conclusion, it is possible that the combined measurement of glucagon, C-
peptide, HbA1c and gender may provide best prediction of hypoglycaemia risk 
and offer the possibility of a combined biomarker. Our study showed that higher 
post-meal glucagon was associated with reduced risk of hypoglycaemia. In 
combination with C-peptide, HbA1c and gender this explained 24% of variation 
in hypoglycaemia rate. The use of this combined biomarker to assess 
hypoglycaemia risk in clinical practice has the potential to individualise and 
improve type 1 diabetes management.  
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Chapter 5: Discussion 
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Chapter 5: Discussion 
 
The work presented in this thesis demonstrates that preserved C-peptide 
production in long duration type 1 diabetes is associated with a reduction in 
hypoglycaemia. Whilst C-peptide appears to be beneficial in avoidance of 
hypoglycaemia we did not find any association with HbA1c or microvascular 
complication rates. During this analysis we also identified the potential for 
MMTT stimulated glucagon to be used as a biomarker of hypoglycaemia risk. 
Higher post-meal glucagon was associated with a lower rate of hypoglycaemia. 
This was independent of glucose, C-peptide and HbA1c. Furthermore, we 
demonstrated that when used in combination, stimulated glucagon, C-peptide 
and HbA1c can explain up to 24% of variance in hypoglycaemia rate.  
This chapter provides a summary of the findings of this thesis and discusses the 
conclusions that have been drawn, implications, limitations and directions for 
future research.  
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Discussion of Chapter 3  
Summary of findings 
This chapter aimed to assess the impact of persistent low-level C-peptide 
production in long duration type 1 diabetes. Analysis was stratified by preserved 
(n=70) and low C-peptide group (n=151), as defined by 90-minute stimulated C-
peptide adjusted for disease duration. We showed that preserved C-peptide 
was associated with markedly reduced rates of hypoglycaemia. Those with 
preserved C-peptide had 21% fewer symptomatic hypoglycaemic episodes per 
month (IRR 0.79, CI 0.68-0.91, p=0.001) and 65% fewer asymptomatic 
episodes (IRR 0.35, CI 0.25-0.48, p<0.001). However, there was no association 
between C-peptide group and HbA1c or prevalence of retinopathy or 
microalbuminuria. Interestingly, daily insulin dose was found to be lower in the 
preserved C-peptide group, 0.68 units/kg vs 0.81 units/kg (p=0.01). 
Conclusions 
Our key finding was that that higher C-peptide is associated with reduced levels 
of hypoglycaemia in long duration type 1 diabetes. Prior to this study little was 
known about the clinical impact of persistent C-peptide in long duration 
diabetes. Our findings are concordant with previous research assessing at 
individuals closer to diagnosis, the majority of which comes from the DCCT. 
However, we did not demonstrate the same relationship between C-peptide and 
reduced HbA1c and microvascular complications as seen in the DCCT. 
(6,54,55) There are a number of potential reasons for this. Firstly, it may be that 
our study was under powered, preventing us from detecting the difference in 
complication rates between the groups. The sample size for our complication 
analysis provided 80% power (alpha 0.05), to detect a difference in proportions 
of 30% for both retinopathy and microalbuminuria.  
Secondly, it may be that the reduced HbA1c and complication rates in the 
DCCT were due to a duration effect. Grouped analysis completed by Steffes et 
al. showed that in the intensively treated individuals, persistent C-peptide 
reduced the incidence of retinopathy development, retinopathy progression, and 
development of nephropathy. However, their analysis was ultimately flawed, as 
duration was different between the groups. Those with undetectable C-peptide 
had a markedly longer disease duration when compared to the minimal, 
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baseline-only and sustained C-peptide groups (8.2 vs 4.5 vs 1.9 vs 2.3 years). 
(6) As such, shorter disease duration may explain the better HbA1c and 
complication rates in the higher and sustained C-peptide groups. This highlights 
the difficulty in disentangling the effect of duration from that of C-peptide, as 
ultimately the two factors are highly correlated. 
A final and most likely explanation for our results comes with the additional 
finding that daily insulin dose was lower in those with preserved C-peptide. This 
could potentially explain why the benefits seen in the DCCT were not present in 
our cohort and suggests that those with preserved C-peptide production 
receiving routine clinical care may be undertreated. C-peptide is not routinely 
measured by clinicians and it is likely the persistent C-peptide status of 
participants was unknown. Currently all people with type 1 diabetes are treated 
to the same glycaemic targets. However, if those with persistent C-peptide were 
more intensively treated it is possible that we would see the HbA1c and 
complication benefits demonstrated by the DCCT.  
Implications 
Our findings raise interesting questions for diabetes management and have the 
potential to impact clinical practice. The apparent under-treatment of individuals 
with preserved C-peptide production may be preventing them from obtaining the 
HbA1c and complication benefits that their persistent C-peptide affords them. 
This demonstrates the importance of identifying individuals with preserved C-
peptide production. Routine monitoring of C-peptide in clinical care would both 
identify such individuals and inform treatment strategy. This could be achieved 
easily using non-invasive UCPCR. UCPCR 120 minutes after a meal and 
MMTT 90-minute C-peptide are highly correlated but a single sample UCPCR is 
much more time and cost efficient. Furthermore, urinary C-peptide is stable for 
72 hours in boric acid, allowing time for the test to be taken (in the clinical 
setting or at home) and the sample to be transported and analysed, making it a 
practical option. (53,72,73) Results could be used to individualise HbA1c and 
blood glucose targets. Those with preserved C-peptide production could receive 
more intensive treatment, with lower HbA1c and blood glucose targets, whilst 
maintaining their lower risk of hypoglycaemia. This may result in improvement in 
HbA1c and microvascular complication rates in this group.  
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Limitations 
Our hypoglycaemia analysis was limited by use of self-reported hypoglycaemia 
questionnaire data. This relied upon participants accurately recognising and 
recalling hypoglycaemic episodes. This can be difficult due to the often-
asymptomatic nature of hypoglycaemia; with impaired hypoglycaemic 
awareness being more common with increasing disease duration. Recording of 
asymptomatic episodes relies upon regular monitoring and recording of blood 
glucose. Furthermore, when present symptoms can be very unspecific, making 
hypoglycaemia difficult to recognise. Alternatively the symptoms themselves 
can make hypoglycaemia difficult to identify and remember, with both cognitive 
impairment and reduced consciousness being common. (25) Research has 
suggested that while severe hypoglycaemic events are typically recalled for up 
to a year, accurate recall of mild episodes is limited to one week. (117) A further 
difficultly with self-reported hypoglycaemia is that approximately 50% of 
hypoglycaemia occurs during sleep. (25) It is likely that the true frequency of 
hypoglycaemia was significantly higher than our self-reported data suggests. 
However, despite this noisy measure of hypoglycaemia, we found there to be a 
strong relationship with C-peptide. This association may be even stronger with 
more precise measurement of hypoglycaemia, such as continuous glucose 
monitoring (CGM). 
Our study was cross-sectional. This prevented us from assessing the 
relationship between persistent C-peptide and first incidence of hypoglycaemia 
and complications; along with the impact of persistent C-peptide on progression 
of microvascular complications. A longitudinal study would allow for assessment 
of the effect of persistent C-peptide on these relationships. Grouped C-peptide 
analysis was also a limiting factor. This meant that we lost information, 
especially at the very low levels of persistent C-peptide within the low C-peptide 
group. It would be interesting to assess the impact of such low levels, which 
have historically been undetectable. However, such an analysis would require a 
remarkably large cohort.  
A further limitation was the exclusion of people with renal failure. This was partly 
due to the recruitment process in which participants were selected from 
UNITED on the basis of their UCPCR. As C-peptide is renally excreted UCPCR 
is not a valid measure of endogenous insulin production in people with renal 
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impairment. (73) As such, exclusion criteria for the TIGI study included renal 
impairment. In addition, people with severe diabetic complications were 
excluded. This was because severe complications can impact T-cell function 
and the TIGI study was designed to investigate immunological factors impacting 
endogenous insulin production. Exclusion of people with severe complications 
means that we were not able to fully assess the impact of C-peptide on 
development of complications. It would be beneficial to assess the impact of 
persistent endogenous insulin production using alternative measures of beta 
cell function in people with more severe complications. However, it can often be 
difficult to engage individuals with poorer health status in clinical studies.  
Our study suggests that under-treatment is responsible for similar HbA1c and 
complication rates in the two C-peptide groups. However, it is possible that 
there is a difference in complication rates that we were unable to detect due to a 
lack of power. The DCCT showed marked differences in complication rates 
between intensively treated responders and non-responders, such as a 50% 
reduced risk of retinopathy progression and 23% relative risk reduction for 
development of microalbuminuria. (54) However, complication rates have 
reduced since the DCCT highlighted the importance of intensive treatment and 
good glycaemic control. (48,49) As such, the difference in complications 
between our C-peptide groups is likely to be significantly smaller. We had 80% 
power (alpha 0.05), to detect a difference in proportions of 30% for both 
retinopathy and microalbuminuria. Our limited power was a result of having a 
relatively small cohort due to complication data only being available in a subset 
of study participants. Had we had a larger cohort, and thus better power, 
perhaps we would have identified a difference in complication rates.  
Analysis was also restricted by assessment of retinopathy. We recorded the 
worst grade of retinopathy reported during the participant’s most recent retinal 
screening appointment prior to recruitment. The diabetic retinal screening 
service grades retinopathy using a digital photograph of each retina following 
pupil dilation. (35,38) In contrast, the DCCT used seven-field stereoscopic 
fundus photographs taken every 6 months by certified photographers. All 
photographers used the Early Treatment Diabetic Retinopathy Study 25 step 
interim scale to grade retinopathy. Progression was defined as a three step 
change. (50) The method used in the DCCT was both more consistent and 
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reliable. In addition, it enabled precise assessment of complication progression 
which we were unable to do in the cross-sectional TIGI study.  
Future research 
The impact of persistent low-level C-peptide in long duration type 1 diabetes is 
an important area of clinical research. While numerous immunotherapy trials 
look to preserve or prolong C-peptide production, little is known about its long 
term effects. Our finding that preserved C-peptide production is associated with 
reduced risk of hypoglycaemia has important implications for clinical practice. It 
is important to validate our findings using a more robust measure of 
hypoglycaemia rate. Continuous glucose monitoring (CGM) will address the 
limitations of self-reported hypoglycaemia, removing participant bias and adding 
additional information such as glucose variability. It would be beneficial to carry 
out CGM across a range of C-peptide levels, looking to assess differences in 
incidence, severity and time spent in hypoglycaemia.   
In addition, a larger prospective study assessing the impact of C-peptide on 
incidence and progression of microvascular complications would be highly 
informative. Evidence regarding the impact of preserved beta cell function 
mainly comes from the DCCT, however, ultimately this is limited by only 
focusing on individuals close to diagnosis and being carried out 30 years ago 
when complication rates were substantially higher. Assessment of the impact of 
C-peptide in long duration type 1 diabetes is needed, using the lessons learned 
from the DCCT regarding the importance of intensive treatment. This would 
require robust assessment and classification of hypoglycaemia and 
complications. Ideally follow-up should run routinely for a number of years, if not 
decades following diagnosis.  
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Discussion of Chapter 4  
Summary of findings 
During our analysis in Chapter 3 we identified that glucagon also predicted 
hypoglycaemia rate. This interesting finding prompted the analysis reported in 
chapter 3 which is discussed here. We investigated MMTT stimulated glucagon 
in the 133 TIGI participants that visited the CRF. Incremental glucagon was 
recorded in 122 participants and in response to the MMTT glucagon increased 
in 53% of participants (65/122), decreased in 15% (18/122) and plateaued in 
32% (39/122). Higher 90-minute glucagon was also associated with older age at 
diagnosis (p=0.04), older age at recruitment (p<0.0001) and increasing disease 
duration (p=0.0002). While there was no association with 90 minute C-peptide 
(p=0.2) higher glucagon was associated with reduced insulin dose (p=0.02).  
Hypoglycaemia analysis showed that higher glucagon at 90 minutes was 
associated with a significantly lower rate of hypoglycaemia. 11% of variation in 
total hypoglycaemia rate was explained by glucagon at 90 minutes alone, with a 
1pmol/l increase reducing rate by 23% (IRR 0.77, CI 0.72-0.81, p<0.0001, 
pseudo R²=0.11). Furthermore, when used in combination with C-peptide and 
HbA1c these biomarkers explained 24% of hypoglycaemic variance. 
Conclusions 
Our findings highlight the potential utility of MMTT stimulated glucagon as a 
biomarker of hypoglycaemia risk. Importantly, the relationship between 
glucagon and hypoglycaemia rate was independent of glucose, HbA1c and C-
peptide. In addition, it was more predictive of hypoglycaemia rate than any of 
these measures. Whilst this is what we would expect in the hypoglycaemic 
setting, it was interesting that inappropriate secretion of glucagon in response to 
a meal explained so much variation in hypoglycaemia rate. Moreover, in 
combination with other biomarkers (C-peptide and HbA1c) a substantial 
proportion of variance in hypoglycaemia rate was explained. This suggests a 
role for a combined biomarker of hypoglycaemic risk which could have 
important implications for clinical practice.   
Furthermore, unlike previous studies we did not identify an association between 
stimulated glucagon and C-peptide. It may be that this was due to the longer 
duration of our cohort. Brown et al. demonstrated that following diagnosis 
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stimulated C-peptide falls while glucagon rises, however, they only studied 
participants for their first year following diagnosis. (89) In contrast, Sherr et al. 
also followed individuals with >2 years duration and found no relationship 
between stimulated C-peptide and glucagon. (90) 
Implications 
Hypoglycaemia poses a significant barrier to management of type 1 diabetes. 
Intensive insulin treatment was demonstrated by the DCCT to significantly 
improve glycaemic control and reduce the development and progression of 
microvascular complications. (50,75) However, insulin induced hypoglycaemia 
remains a barrier to achieving strict glycaemic control. (29) There are currently 
no biomarkers used to predict hypoglycaemia risk, however, meal stimulated 
glucagon has the potential to do so. This would provide an invaluable tool 
clinicians could use to identify individuals at higher risk of hypoglycaemia, and 
subsequently individualise treatment strategy. Those at higher risk may require 
less intensive treatment, with higher blood glucose and HbA1c targets, to avoid 
hypoglycaemia. Furthermore, use of a combined biomarker, explaining even 
more variation in hypoglycaemia rate, would strengthen this tool. 
Limitations 
As discussed in the discussion for Chapter 3 our study is limited by its use of 
self-reported hypoglycaemia questionnaire data. However, despite this less 
precise measure, hypoglycaemia still displayed a striking association with 
MMTT stimulated glucagon.  
A further limitation of this analysis is the stability of glucagon. Historically there 
have been problems with both sensitivity and specificity in glucagon assays. 
However, recent development of a sandwich ELISA used to identify intact 
glucagon through antibodies to a specific combination of N- and C- terminal 
epitopes has overcome this barrier. (95) While we were able to utilise the 
Mercodia glucagon ELISA there were concerns regarding degradation of 
glucagon. For this reason we did not include TIGI participants who were visited 
at home as we could not be certain how long samples took to arrive at the 
laboratory. Whilst samples collected at the CRF were rapidly spun and then 
stored at -80⁰C prior to analysis, there was still a degree of uncertainty 
regarding the amount of degradation. While it is important to take account of 
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this it makes our findings more remarkable. Despite potential degradation, the 
association between higher MMTT stimulated glucagon and lower rate of 
hypoglycaemia was highly significant and explained a substantial amount of 
variation in hypoglycaemia rate both alone (11%) and in combination with C-
peptide and HbA1C (24%). 
A final limitation is the cohort size for the hypoglycaemia analysis, n=72. 
Unfortunately, hypoglycaemia questionnaires were not given to the participants 
recruited to the study in its early stages. While analysis showed that those with 
and without hypoglycaemia questionnaires were broadly similar, this 
significantly reduced the sample size.  
Future research 
Validating the association between glucagon and hypoglycaemia in a large 
cohort would add strength to our findings. We plan to analyse data from other 
studies where participants have both MMTT data and hypoglycaemia 
questionnaires, with the view to establish the utility of MMTT stimulated 
glucagon as a biomarker of hypoglycaemia risk.  
In order to overcome the limitations of self-reported hypoglycaemia data a CGM 
study would be useful, as outlined in the discussion for chapter 3. This would be 
highly valuable in validating the use of MMTT stimulated glucagon as a 
biomarker of hypoglycaemia risk. Looking at C-peptide and HbA1c in the same 
cohort would further this research. Looking toward the development of a tool in 
which, these biomarkers are combined to assess hypoglycaemic risk in clinical 
practice and inform treatment strategy.  
Further investigation is also needed into the reason for post-meal glucagon 
being a good marker of hypoglycaemic risk. In health glucagon is secreted in 
response to falling blood glucose levels and is supressed following a meal. 
Glucagon dysfunction has been repeatedly reported in type 1 diabetes, with 
inappropriate secretion following meal stimulation being demonstrated. 
(7,89,90) However, we are unable to fully explain why a higher MMTT 
stimulated glucagon is associated with reduced hypoglycaemia. This is 
counterintuitive as glucagon’s role in protection from hypoglycaemia occurs at 
low blood glucose levels, not post meal. It would be logical to assume that with 
increasing glucagon dysregulation, such as a heightened response following a 
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meal, hypoglycaemia would become more common. We found this was not the 
case, but the opposite, higher post-meal glucagon was associated with reduced 
rate of hypoglycaemia. As such, hypoglycaemic clamp studies would be helpful 
in beginning to understand the physiology behind this association in people with 
a range of MMTT glucagon stimulated responses. Ideally this would be 
combined with CGM to assess glucose variation along with measures of 
hypoglycaemia.  
It would also be interesting to study whether the association of glucagon with 
hypoglycaemia remains in those with undetectable beta cell function. The 
relationship between C-peptide and glucagon in type 1 diabetes is not fully 
understood. It has been suggested that in health glucagon secretion is 
mediated by endogenous insulin production, whereas, in type 1 diabetes 
glucagon secretion becomes reliant on blood glucose level. (7) Therefore, 
investigating glucagon post-meal and using hypoglycaemic clamps in people 
with very little or no C-peptide production could further explain this relationship. 
Cohorts in which this could be investigated include those selected to receive 
islet cell transplant and people impaired hypoglycaemic awareness recruited to 
HypoCOMPaSS. Our study has also highlighted the potential importance of 
including glucagon with insulin in closed-system pumps, an area of ongoing 
research. (115,116) 
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Overall thesis conclusions  
 
Recent research has shown that people with long duration type 1 diabetes 
continue to secrete C-peptide at low levels for many years. (51–53) However, 
very little is known about the impact of persistent C-peptide in long duration type 
1 diabetes. The findings from this thesis demonstrate that persistent C-peptide 
in long duration diabetes is associated with a reduced rate of hypoglycaemia. 
Furthermore, during this analysis we also identified that MMTT stimulated 
glucagon has the potential to be used as a biomarker of hypoglycaemic risk. 
With higher stimulated glucagon being associated with a reduced rate of 
hypoglycaemia.  
Together these findings have the potential to change clinical practice, allowing 
identification of individuals at low and high hypoglycaemic risk. Currently there 
are no biomarkers used to assess risk of hypoglycaemia. We have shown that 
when used in combination, glucagon, C-peptide and HbA1c explain 24% of 
variance in hypoglycaemic rate. Using the combination of these biomarkers to 
evaluate hypoglycaemic risk would be an invaluable tool for clinical practice. 
Targeted intensification of treatment in people with low hypoglycaemic risk 
could potentially improve HbA1c and reduce microvascular complication rates 
within this group.  
Despite the limitations associated with self-reported hypoglycaemia, both C-
peptide and glucagon demonstrated strong associations with hypoglycaemia 
rate. Future research should look to validate these associations with a more 
precise measure of hypoglycaemia, such as continuous glucose monitoring. 
Perhaps the combination of C-peptide, glucagon and HbA1c would be an even 
stronger predictor of hypoglycaemia risk if hypoglycaemia was measured more 
precisely. 
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Site 
 
 
 
Patient ID  
 
 
Date Questionnaire Completed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MODIFIED CLARKE/EDINBURGH HYPOGLYCAEMIA HISTORY 
 
1. Tick the category that best describes you (tick one only) 
£ I always have symptoms when my blood sugar is low 
£ I sometimes have symptoms when my blood sugar is low 
£ I no longer have symptoms when my blood sugar is low 
 
2. Have you lost some of the symptoms that used to occur when your blood sugar was 
low? 
£ Yes      £ No 
 
3. In the past year, how often have you had hypoglyaemic episodes, where you might 
feel confused, disorientated, or lethargic and were unable to treat yourself? 
£ Never  £ Once or twice  £ Every other month 
£ Once a month £ More than once a month  
 
4. In the past 6 months, how often have you had hypoglyaemic episodes, where you 
were unconscious or had a seizure and needed glucagon or intravenous glucose? 
£ Never  £ 5 times   £ 10 times 
£ 1 time  £ 6 times   £ 11 times 
£ 2 times  £ 7 times   £ 10 times 
£ 3 times  £ 8 times 
£ 4 times  £ 9 times 
   
5. How often in the last month have you had readings <3.5mmol/l with symptoms? 
£ Never  £ 1-3 times  £ 1 time/week 
£ 2-3 times/week £ 4-5 times/week £ almost daily 
 
6. How often in the last month have you had readings <3.5mmol/l without any 
symptoms 
£ Never  £ 1-3 times  £ 1 time/week 
£ 2-3 times/week £ 4-5 times/week £ almost daily 
 
7. How low does your blood sugar need to go before you feel symptoms? 
£ 3.4-3.9 mmol/l  £ 2.9-3.3 mmol/l £ 2.2-2.7 mmol/l £ <2.2 
mmol/l  
 
8. To what extent can you tell by your symptoms that your blood sugar is low? 
£ Never  £ Rarely £ Sometimes  £ Often  £ 
Always 
 
Continued overleaf ……….  
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EDINBURGH HYPOGLYCAEMIA SURVEY 
(INCLUDING THE GOLD SCORE) 
1. Please score the extent to which you experience the following symptoms 
during a typical daytime hypoglycaemic episode (circle a number for each 
symptom) 
Not present     present a 
great deal 
Confusion    1 2 3 4 5 6 7 
Sweating    1 2 3 4 5 6 7 
Drowsiness    1 2 3 4 5 6 7 
Weakness    1 2 3 4 5 6 7 
Dizziness    1 2 3 4 5 6 7 
Warmth    1 2 3 4 5 6 7 
Difficulty speaking   1 2 3 4 5 6 7 
Pounding heart    1 2 3 4 5 6 7 
Inability to concentrate   1 2 3 4 5 6 7 
Blurred vision    1 2 3 4 5 6 7 
Hunger     1 2 3 4 5 6 7 
Nausea     1 2 3 4 5 6 7 
Anxiety     1 2 3 4 5 6 7 
Tiredness    1 2 3 4 5 6 7 
Tingling lips    1 2 3 4 5 6 7 
Trembling    1 2 3 4 5 6 7 
Headache    1 2 3 4 5 6 7 
 
2. Do you know when your hypos are commencing? Please circle a number: 
 
Always aware        Never aware 
Awareness   1 2 3 4 5 6 7 
 
 
 
 
Questionnaires reproduced with kind permission from UK Islet Transplant Consortium. Minimally modified Clarke's 
questionnaire in GSTT 1901 2009 reproduced with kind permission from Ming Ming Teh. Edinburgh Hypoglycaemia Survey 
(including the Gold Score) reproduced with kind permission from Prof Brian Frier.  
Further Comments: 
